<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        188-368-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FENIXOR 50MG TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENLAFAXINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX16 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fenixor&trade; contains the active substance venlafaxine.<br />Fenixor&trade; is an antidepressant that belongs to a group of medicines called serotonin<br />and norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to<br />treat depression and other conditions such as anxiety disorders. It is thought that<br />people who are depressed and/or anxious have lower levels of serotonin and<br />noradrenaline in the brain. It is not fully understood how antidepressants work, but<br />they may help by increasing the levels of serotonin and noradrenaline in the brain.<br />Fenixor&trade; is a treatment for adults with depression. Treating depression properly is<br />important to help you get better. If it is not treated, your condition may not go away<br />and may become more serious and more difficult to treat.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Fenixor&trade;<br />&bull; If you are allergic to venlafaxine or any of the other ingredients of this medicine<br />(listed in section 6).<br />&bull; If you are also taking, or have taken any time within the last 14 days, any medicines<br />known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat<br />depression or Parkinson&rsquo;s disease. Taking an irreversible MAOI together with other<br />medicines, including Venlafaxine, can cause serious or even life-threatening side<br />effects. Also, you must wait at least 7 days after you stop taking Fenixor&trade; before you<br />take any irreversible MAOI (see also the section &ldquo;Other medicines and Fenixor&trade; &rdquo;<br />and the information in that section about &lsquo;Serotonin Syndrome&rsquo;).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Fenixor&trade;:<br />&bull; If you use other medicines that taken together with Fenixor&trade; could increase the risk<br />of developing serotonin syndrome (see the section &ldquo;Other medicines and<br />Fenixor&trade; &rdquo;).<br />&bull; If you have eye problems, such as certain kinds of glaucoma (increased pressure in<br />the eye).<br />&bull; If you have a history of high blood pressure.<br />&bull; If you have a history of heart problems.<br />&bull; If you have been told you have an abnormal heart rhythm.<br />&bull; If you have a history of fits (seizures).<br />&bull; If you have a history of low sodium levels in your blood (hyponatraemia).<br />&bull; If you have a tendency to develop bruises or a tendency to bleed easily (history of<br />bleeding disorders), or if you are taking other medicines that may increase the risk of<br />bleeding e.g., warfarin (used to prevent blood clots).<br />&bull; If you have a history of, or if someone in your family has had, mania or bipolar<br />disorder (feeling over-excited or euphoric).<br />&bull; If you have a history of aggressive behaviour.<br />&bull; If you use weight loss preparations; it is not recommended to use them together<br />with Fenixor&trade;.<br />Fenixor&trade; may cause a sensation of restlessness or an inability to sit or stand still<br />during the first few weeks of treatment. You should tell your doctor if this happens to<br />you.<br />Tell the doctor that you are taking Fenixor&trade; if you have to provide a urine sample.<br />Thoughts of suicide and worsening of your depression or anxiety disorder<br />If you are depressed and/or have anxiety disorders, you can sometimes have thoughts<br />of harming or killing yourself. These may be increased when you first start taking<br />antidepressants, since these medicines all take time to work, usually about two<br />weeks, but sometimes longer.<br />You may be more likely to think like this:<br />&bull; If you have previously had thoughts about killing or harming yourself.<br />&bull; If you are a young adult. Information from clinical trials has shown an increased<br />risk of suicidal behaviour in young adults (less than 25 years old) with psychiatric<br />conditions who were treated with an antidepressant.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor<br />or go to a hospital straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or have<br />an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you<br />if they think your depression or anxiety is getting worse, or if they are worried about<br />changes in your behaviour.<br />Dry mouth<br />Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase<br />the risk of tooth decay (caries). Therefore, you should take special care in your dental<br />hygiene.<br />Diabetes<br />Your blood glucose levels may be altered due to Fenixor&trade;. Therefore, the dosage of<br />your diabetes medicines may need to be adjusted.<br />Children and adolescents<br />Fenixor&trade; should normally not be used for children and adolescents under 18 years.<br />Also, you should know that patients under 18 have an increased risk of side effects,<br />such as suicide attempt, suicidal thoughts and hostility (predominantly aggression,<br />oppositional behaviour and anger) when they take this class of medicines. Despite<br />this, your doctor may prescribe Fenixor&trade; for patients under 18 because he/she<br />decides that this is in their best interests. If your doctor has prescribed this medicine<br />for a patient under 18, and you want to discuss this, please go back to your doctor.<br />You should inform your doctor if any of the symptoms listed above develop or<br />worsen when patients under 18 are taking Fenixor&trade;. Also, the long-term safety<br />effects concerning growth, maturation and cognitive and behavioural development of<br />Fenixor&trade; in this age group has not yet been demonstrated.<br />Other medicines and Fenixor&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take<br />any other medicines. Your doctor should decide whether you can take Fenixor&trade; with<br />other medicines.<br />Do not start or stop taking any medicines, including those bought without a<br />prescription, natural and herbal remedies, before checking with your doctor or<br />pharmacist.<br />&bull; Monoamine oxidase inhibitors which are used to treat depression or Parkinson&rsquo;s<br />disease must not be taken with Fenixor&trade;. Tell your doctor if you have taken these<br />medicines within the last 14 days. (MAOIs: see the section &ldquo;What you need to know<br />before you take Fenixor&trade;&rdquo;).<br />&bull; Serotonin syndrome:<br />A potentially life-threatening condition or Neuroleptic Malignant Syndrome<br />(NMS)-like reactions (see the section &ldquo;Possible Side Effects&rdquo;) may occur with<br />venlafaxine treatment, particularly when taken with other medicines.<br />Examples of these medicines include:<br />- Triptans (used for migraine)<br />- Medicines to treat depression, for instance SNRIs, SSRIs, tricyclics, or medicines<br />containing lithium<br />- Medicines containing linezolid, an antibiotic (used to treat infections)<br />- Medicines containing moclobemide, a reversible MAOI (used to treat depression)<br />- Medicines containing sibutramine (used for weight loss)<br />- Medicines containing tramadol, fentanyl, tapentadol, pethidine, or<br />pentazocine (a pain-killer)<br />- Medicines containing dextromethorphan (used to treat coughing)<br />- Medicines containing methadone (used to treat opioid drug addiction or severe<br />pain)<br />- Medicines containing methylene blue (used to treat high levels of methaemoglobin<br />in the blood)<br />- Products containing St. John&rsquo;s Wort (also called Hypericum perforatum, a natural<br />or herbal remedy used to treat mild depression)<br />- Products containing tryptophan (used for problems such as sleep and depression)<br />- Antipsychotics (used to treat a disease with symptoms such as hearing, seeing or<br />sensing things which are not there, mistaken beliefs, unusual suspiciousness, unclear<br />reasoning and becoming withdrawn)<br />Signs and symptoms of serotonin syndrome may include a combination of the<br />following:<br />restlessness, hallucinations, loss of coordination, fast heart beat, increased body<br />temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma,<br />nausea, vomiting.<br />In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant<br />Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever,<br />fast heart beat, sweating, severe muscle stiffness, confusion, increased muscle<br />enzymes (determined by a blood test).<br />Tell your doctor immediately, or go to the casualty department at your nearest<br />hospital if you think serotonin syndrome is happening to you.<br />You must tell your doctor if you are taking medicines that can affect your heart<br />rhythm. Examples of these medicines include:<br />&bull; Antiarrhythmics such as quinidine, amiodarone, sotalol or dofetilide (used to treat<br />abnormal heart rhythm)<br />&bull; Antipsychotics such as thioridazine (See also Serotonin syndrome above)<br />&bull; Antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections)<br />&bull; Antihistamines (used to treat allergy)<br />The following medicines may also interact with Fenixor&trade; and should be used with<br />caution. It is especially important to mention to your doctor or pharmacist if you are<br />taking medicines containing:<br />&bull; Ketoconazole (an antifungal medicine)<br />&bull; Haloperidol or risperidone (to treat psychiatric conditions)<br />&bull; Metoprolol (a beta blocker to treat high blood pressure and heart problems)<br />&bull; Imipramine (to treat depression)<br />&bull; Diazepam (to treat anxiety or sleeping problems)<br />&bull; Indinavir (to treat HIV/AIDS)<br />Tell your doctor if you are taking oral contraceptives.<br />Fenixor&trade; with food, drink and alcohol<br />Fenixor&trade; should be taken with food (see section 3 &ldquo;How to take Fenixor&trade; &rdquo;). You<br />should avoid alcohol while you are taking Fenixor&trade;.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />You should use Fenixor&trade; only after discussing the potential benefits and the potential<br />risks to your unborn child with your doctor.<br />Make sure your midwife and/or doctor knows you are on Fenixor&trade;. When taken<br />during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition<br />in babies, called persistent pulmonary hypertension of the newborn (PPHN), making<br />the baby breathe faster and appear bluish. These symptoms usually begin during the<br />first 24 hours after the baby is born. If this happens to your baby you should contact<br />your midwife and/or doctor immediately.<br />If you are taking this medicine during pregnancy, in addition to having trouble<br />breathing, another symptom your baby might have when it is born is not feeding<br />properly. If your baby has these symptoms when it is born and you are concerned,<br />contact your doctor and/or midwife who will be able to advise you.<br />Fenixor&trade; passes into breast milk. There is a risk of an effect on the baby. Therefore,<br />you should discuss the matter with your doctor, and he/she will decide whether you<br />should stop breast-feeding or stop the therapy with this Fenixor&trade;.<br />Driving and using machines<br />Do not drive or use any tools or machines until you know how Fenixor&trade; affects you.<br />Important information about some of the ingredients of Fenixor&trade;<br />This product contains lactose. If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Fenixor&trade; exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure.<br />The usual recommended starting dose is 75 mg per day in divided doses, two or three<br />times a day. The dose can be raised by your doctor gradually and, if needed, even up<br />to a maximum dose of 375 mg daily for depression.<br />Take Fenixor&trade; at approximately the same time each day, either in the morning or in<br />the evening.<br />Fenixor&trade; should be taken with food.<br />If you have liver or kidney problems, talk to your doctor, since your dose of this<br />medicine may need to be different.<br />Do not stop taking this medicine without talking to your doctor (see the section &ldquo;If<br />you stop taking Fenixor&trade;&rdquo;).<br />If you take more Fenixor&trade; than you should<br />Call your doctor or pharmacist immediately if you take more of Fenixor&trade; than the<br />amount prescribed by your doctor.<br />The symptoms of a possible overdose may include a rapid heart beat, changes in<br />level of alertness (ranging from sleepiness to coma), blurred vision, seizures or fits,<br />and vomiting.</p><p>If you forget to take Fenixor&trade;<br />If you miss a dose, take it as soon as you remember. However, if it is time for your<br />next dose, skip the missed dose and take only a single dose as usual. Do not take a<br />double dose to make up for a forgotten dose. Do not take more than the daily amount<br />of Fenixor&trade; that has been prescribed for you in one day.<br />If you stop taking Fenixor&trade;<br />Do not stop taking your treatment or reduce the dose without the advice of your<br />doctor even if you feel better. If your doctor thinks that you no longer need Fenixor<br />&trade;, he/she may ask you to reduce your dose slowly before stopping treatment<br />altogether. Side effects are known to occur when people stop using this medicine,<br />especially when it is stopped suddenly or the dose is reduced too quickly. Some<br />patients may experience symptoms such as tiredness, dizziness, light-headedness,<br />headache, sleeplessness, nightmares, dry mouth, loss of appetite, nausea, diarrhoea,<br />nervousness, agitation, confusion, ringing in the ears, tingling or rarely electric shock<br />sensations, weakness, sweating, seizures, or flu-like symptoms.<br />Your doctor will advise you on how you should gradually discontinue Fenixor&trade;<br />treatment. If you experience any of these or other symptoms that are troublesome, ask<br />your doctor for further advice.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />If any of the following happen, do not take more Fenixor&trade;. Tell your doctor<br />immediately, or go to the casualty department at your nearest hospital:<br />&bull; Chest tightness, wheezing, trouble swallowing or breathing<br />&bull; Swelling of the face, throat, hands, or feet<br />&bull; Feeling nervous or anxious, dizziness, throbbing sensations, sudden reddening of<br />the skin and/or a warm feeling<br />&bull; Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)<br />&bull; Signs and symptoms of serotonin syndrome which may include restlessness,<br />hallucinations, loss of coordination, fast heart beat, increased body temperature, fast<br />changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting.<br />In its most severe form, serotonin syndrome can resemble Neuroleptic malignant<br />syndrome (NMS). Signs and symptoms of NMS may include a combination of fever,<br />fast heart beat, sweating, severe muscle stiffness, confusion, increased muscle<br />enzymes (determined by a blood test).<br />&bull; Yellow skin or eyes, itchiness or dark urine, which may be symptoms of<br />inflammation of the liver (hepatitis)<br />&bull; Thoughts of harming or killing yourself - cases of suicidal ideation and suicidal<br />behaviours have been reported during venlafaxine therapy or early after treatment<br />discontinuation (see section 2, Do not take Fenixor&trade;)<br />&bull; Reduced number of platelets in your blood, leading to an increased risk of bruising<br />or bleeding; blood disorders which may lead to an increased risk of infection that may<br />present in e.g. high fever or sore throat<br />Serious side effects<br />If you notice any signs of the following, you may need urgent medical attention:<br />&bull; Coughing, wheezing, shortness of breath and a high temperature<br />&bull; Black (tarry) stools or blood in stools<br />&bull; Heart problems, such as fast or irregular heart rate, increased blood pressure<br />&bull; Eye problems, such as blurred vision, dilated pupils<br />&bull; Nerve problems, such as pins and needles, movement disorder, seizures or fits<br />&bull; Psychiatric problems, such as hyperactivity and euphoria (feeling unusually<br />overexcited)<br />&bull; Treatment withdrawal (see the section &ldquo;How to take Fenixor&trade;, If you stop taking<br />Fenixor&trade;&rdquo;)<br />&bull; Prolonged bleeding - if you cut or injure yourself, it may take slightly longer than<br />usual for bleeding to stop.<br />Other reported side effects<br />Very common (may affect more than 1 in 10 people)<br />Digestive disorders: nausea ; dry mouth<br />Nervous system disorders: headache<br />Skin disorders: sweating (including night sweats)<br />Common (may affect up to 1 in 10 people)<br />Breathing disorders: yawning<br />Digestive disorders: appetite decreased; constipation; vomiting; diarrhoea<br />Heart or circulation disorders: increase in blood pressure; flushing; palpitations<br />General: weakness (asthenia); fatigue; chills<br />Metabolism/nutritional disorders: increased cholesterol<br />Nervous system disorders: abnormal dreams; decreased libido; increased muscle<br />tonus; insomnia; nervousness; pins and needles; drowsiness; tremor; feeling separated<br />(or detached) from yourself and reality<br />Reproductive and sexual disorders: abnormal ejaculation/orgasm (males); lack of<br />orgasm; erectile dysfunction (impotence); menstrual irregularities such as increased<br />bleeding or increased irregular bleeding<br />Sight and hearing disorders: visual disturbance including blurred vision: dilated<br />pupils; inability of the eye to automatically change focus from distant to near objects ;<br />ringing in the ears (tinnitus)<br />Urinary system disorder: difficulties passing urine; increased frequency in urination<br />Uncommon (may affect up to 1 in 100 people)<br />Blood disorders: bruising; vomiting blood;<br />Digestive disorder: grinding of the teeth<br />Heart or circulation disorders: feeling dizzy (particularly when standing up too<br />quickly), fainting, fast heartbeat<br />General: sensitivity to sunlight, general swelling of the skin especially the face,<br />mouth, tongue, throat area or hands and feet and/or a raised itchy rash (hives) may be<br />present<br />Breathing disorders: shortness of breath<br />Metabolism/nutritional disorders: weight gain, weight loss<br />Nervous system disorders: lack of feeling or emotion; hallucinations; feeling<br />separated (or detached) from reality; involuntary movement of the muscles; agitation;<br />impaired coordination and balance: a sensation of restlessness or an inability to sit or<br />stand still, feeling over-excited<br />Reproductive and sexual disorders: abnormal orgasm (females)<br />Skin disorders: rash; abnormal hair loss<br />Sight and hearing disorders: altered taste sensation<br />Urinary system disorders: inability to pass urine<br />Rare (may affect up to 1 in 1,000 people)<br />Nervous system disorders, seizures or fits, over activity, racing thoughts and<br />decreased need for sleep<br />(mania).<br />Urinary system disorders: inability to control urination<br />Frequency Not known(frequency cannot be estimated from the available data)<br />Digestive disorders: severe abdominal or back pains (which could indicate a serious<br />problem in the gut, liver or pancreas)<br />General: swollen face or tongue, shortness of breath or difficulty breathing, often with<br />skin rashes (this may be a serious allergic reaction)<br />Heart or circulation disorders: decrease in blood pressure; abnormal, rapid or irregular<br />heart beat, which could lead to fainting , unexpected bleeding, e.g. bleeding gums,<br />blood in the urine or in vomit, or the appearance of unexpected bruises or broken<br />blood vessels (broken veins)<br />Metabolism/nutritional disorders: slight changes in blood levels of liver enzymes;<br />decrease in blood sodium levels; excessive water intake (known as SIADH);<br />abnormal breast milk production<br />Muscle disorders: unexplained muscle pain, tenderness or weakness<br />(rhabdomyolysis)<br />Nervous system disorders: euphoric feelings, drowsiness, sustained rapid eye<br />movement, clumsiness, restlessness, feeling of being drunk, sweating or rigid<br />muscles, which are symptoms of serotonergic syndrome; disorientation often<br />accompanied by hallucination (delirium); stiffness, spasms and involuntary<br />movements of the muscles; vertigo; aggression<br />Skin disorders: skin rash, which may lead to severe blistering and peeling of the skin;<br />itching; mild rash<br />Sight and hearing disorders: severe eye pain and decreased or blurred vision<br />Fenixor&trade; sometimes causes unwanted effects that you may not be aware of, such as<br />increases in blood pressure or abnormal heart beat; slight changes in blood levels of<br />liver enzymes, sodium or cholesterol. More rarely, Fenixor&trade; may reduce the function<br />of platelets in your blood, leading to an increased risk of bruising or bleeding.<br />Therefore, your doctor may wish to do blood tests occasionally, particularly if you<br />have been taking Fenixor&trade; for a long time.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any<br />possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not use this medicine after the expiry date, which is stated on the packaging.<br />Do not store above 30 &deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Venlafaxine Hydrochloride.<br />Each tablet contains 28.280 mg, 42.420 mg, 56.560 mg and 84.840 mg of<br />Venlafaxine Hydrochloride equivalent to 25 mg, 37.5 mg, 50 mg and 75 mg<br />Venlafaxine respectively.<br />The other ingredients are: Lactose monohydrate, microcrystalline cellulose, sodium<br />Starch Glycolate, Iron oxide Yellow, Colloidal silicon dioxide &amp; Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                25 mg: Pale yellow to yellow colored, Mottled round, biconvex tablets, debossed with
"JP" on one side and "AN" on the other side.
37.5 mg: Pale Yellow to Yellow colored, Mottled round, biconvex tablets debossed
with ‘AP’ on one side and ‘JP’ on other side.
50 mg: Pale yellow to yellow colored, Mottled round tablets debossed with ‘JP’ on
one side and ‘154’ on other side.
75 mg: Pale yellow to yellow colored, Mottled round, biconvex tablets debossed with
‘155’ on one side and ‘JP’ on other side along with break line.
Fenixor™ tablets available in 25 mg, 37.5 mg, 50 mg and 75 mg tablets in boxes of
30 tablets each.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and<br />Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>1. ما هو فينيكسور&trade;؟ وفيم يُستخدم</p><p>&nbsp;</p><p>يحتوي فينيكسور&trade; على المادة الفعالة فينلافاكسين.</p><p>يعد فينيكسور&trade; مضادًا للاكتئاب ينتمي إلى مجموعة من الأدوية تسمى مثبطات إعادة امتصاص السيروتونين والنورابينفرين (النورادرينالين). تستخدم هذه الفئة من الأدوية في علاج الاكتئاب وحالات أخرى مثل اضطرابات القلق. يُعتقد أن الأشخاص الذين يعانون من الاكتئاب و/أو القلق لديهم مستويات سيروتونين ونورادرينالين أقل في الدماغ. لم تُكتَشف آلية عمل مضادات الاكتئاب بالضبط، لكنها قد تساعد في التحسن عن طريق زيادة مستويات سيروتونين ونورادرينالين في الدماغ.</p><p>يُعد فينيكسور&trade; علاجًا للبالغين الذين يُعانون من الاكتئاب. ويُستخدم أيضًا في علاج اضطرابات القلق التالية لدى البالغين: اضطراب القلق المعمم، واضطراب القلق الاجتماعي (الخوف من المواقف الاجتماعية أو تجنبها) واضطراب الذعر (نوبات الذعر). لا بد من علاج الاكتئاب أو اضطرابات القلق حتى تتحسن حالتك. إذا لم يتم علاج حالتك، قد لا تزول أو قد تصبح أكثر خطورة وأصعب في علاجها.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>2. ما تحتاج إلى معرفته قبل تناوُل فينيكسور&trade;</p><p>لا تتناول فينيكسور&trade; في الحالات التالية:</p><p>&nbsp;</p><p>&bull; إذا كنت تعاني من حساسية تجاه فينلافاكسين أو أيٍّ من المكونات الأخرى الداخلة في تركيب هذا الدواء. (المدرجة في قسم 6)</p><p>&bull; إذا كنت تتناول أو قد تناولت مؤخرًا (في خلال آخر أسبوعين) أي أدوية تُعرف بمثبطات أوكسيداز أحادي الأمين غير الانعكاسية، والتي تستخدم في علاج الاكتئاب أو مرض باركنسون. قد يؤدي تناوُل أحد مثبطات أوكسيداز أحادي الأمين غير الانعكاسية مع فينيكسور&trade; إلى حدوث آثار جانبية خطيرة أو مهددة للحياة. يجب أيضًا أن تتنظر 7 أيام على الأقل بعد التوقف عن تناول فينيكسور&trade; قبل أن تبدأ في تناول أي من مثبطات أوكسيداز أحادي الأمين.</p><p>(انظر قسم بعنوان &quot;تناول أدوية أخرى مع فينيكسور&trade;&quot; والمعلومات المذكورة في هذا القسم عن &quot;متلازمة السيروتونين&quot;).</p><p>&nbsp;</p><p>تحذيرات واحتياطات</p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول فينيكسور&trade;:</p><p>&bull; إذا كنت تستخدم أي أدوية أخرى مع فينيكسور&trade; فقد يزداد خطر الإصابة بمتلازمة السيروتونين (انظر قسم تناول أدوية أخرى مع فينيكسور&trade;).</p><p>&bull; إذا كنت تعاني من مشكلة في العين، مثل بعض أنواع الزَرَق &quot;جلوكوما&quot; (تزايد الضغط داخل العين).</p><p>&bull; إذا كان لديك تاريخ مرضي من ارتفاع ضغط الدم.</p><p>&bull; إذا كان لديك تاريخ من الإصابة بمشاكل في القلب.</p><p>&bull; إذا تم إبلاغك بأنك تعاني من عدم انتظام نظم القلب.</p><p>&bull; إذا كان لديك تاريخ مرضي من الإصابة بنوبات تشنج.</p><p>&bull; إذا كان لديك تاريخ مرضي من انخفاض مستويات الصوديوم في الدم.</p><p>&bull; إذا كنت تُعانى من الميل إلى الإصابة بكدمات أو النزف بسهولة (تاريخ مرضي من اضطرابات النزف)، أو إذا كنت تتناول أي أدوية أخرى قد تزيد من خطر النزف، مثل: وارفارين (يستخدم في الوقاية من جلطات الدم).</p><p>&bull; إذا كان لديك أو لدى فرد في عائلتك تاريخ مرضي من الإصابة بالهوس أو اضطراب ثنائي القطب (الشعور بالحماس المفرط أو البهجة).</p><p>&bull; إذا كان لديك تاريخ مرضي من السلوك العدواني.</p><p>قد يسبب فينيكسور&trade; شعورًا بالتململ أو عدم القدرة على البقاء بوضع ثابت أثناء الأسابيع الأولى من العلاج. يجب عليك أن تخبر طبيبك إذا حدث ذلك.</p><p>الأفكار الانتحارية وتفاقم الاكتئاب أو اضطراب القلق</p><p>إذا كنت مكتئبًا و/أو تعاني من اضطرابات قلق، فمن الممكن أن تفكر أحيانًا في إيذاء نفسك أو الانتحار. قد تزداد هذه الأفكار عند بدء تناوُل مضادات الاكتئاب لأول مرة؛ نظرًا إلى أن جميع هذه الأدوية تستغرق وقتًا حتى تعطي مفعولًا، عادةً يستغرق الأمر أسبوعين تقريبًا، ولكن في بعض الأحيان يستغرق فترة أطول.</p><p>قد تكون أكثر عُرضة للتفكير على هذا النحو في الحالات الآتية:</p><p>&bull; إذا سبق لك أن فكرت في الانتحار أو إيذاء نفسك.</p><p>&bull; إذا كنت شاب بالغ صغير السن. أظهرت المعلومات المنتقاة من التجارب السريرية ارتفاع نسبة خطورة السلوك الانتحاري لدى البالغين الذين تقل أعمارهم عن ٥٢ عامًا ويُعانون من حالات نفسية وعُولجوا بأحد مضادات الاكتئاب.</p><p>إذا ساورتك أفكار بالانتحار أو إيذاء نفسك في أي وقت، فاتصل بطبيبك أو اذهب إلى المستشفى فورًا.</p><p>قد تجد أنه من المفيد أن تخبر قريبًا أو صديقًا مقربًا بأنك تعاني من الاكتئاب أو مصاب باضطراب قلق، وأن تطلب منهم قراءة هذه النَّشرة. قد تطلب منهم أن يخبروك إذا كانوا يعتقدون أن الاكتئاب أو القلق لديك يتدهور، أو إذا كانوا قلقين بشأن تغييرات في سلوكك.</p><p>جفاف الفم</p><p>قد تم الإبلاغ عن إصابة ٠١ ٪ من المرضى الذين يعالجون بفينلافاكسين بجفاف الفم. قد يزيد هذا من خطر الإصابة بتسوس الأسنان (نخر). لذا يجب أن تولي عناية خاصة بنظافة الأسنان.</p><p>مرض السُّكري</p><p>قد تتغير مستويات الجلوكوز في دمك نتيجة تناول فينيكسور&trade;. لذا، قد يلزم تعديل جرعات أدوية مرض السكري.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p>عادةً، يجب ألا يتم استخدام فينيكسور&trade; للأطفال والمراهقين أقل من ٨١ عامًا. يجب أيضًا أن تعرف أن المرضى الذين تقل أعمارهم عن ٨١ عامًا معرَّضون لنسبة خطورة مرتفعة للإصابة بآثار جانبية مثل محاولة الانتحار والأفكار الانتحارية والعداء (غالبًا عدوانية، وسلوك معارض، وغضب) عند تناوُل هذه الفئة من الأدوية. ورغم ذلك، فقد يصف طبيبك هذا الدَّواء لمن هم أقل من ٨١ عامًا؛ لأنه ربما يرى أنه يصب في صالح المريض. إذا وصف طبيبك هذا الدواء لعلاج مريض يقل عمره عن ٨١ عامًا، وتريد مناقشة ذلك، فيُرجى الرجوع إلى طبيبك. يجب عليك إبلاغ طبيبك إذا ظهرت أي من الأعراض المذكورة أعلاه أو تفاقمت بعد تناوُل المرضى الذين تقل أعمارهم عن ٨١ عامًا فينيكسور&trade;. كذلك، لم يتم التَّأكد حتى الآن من تأثيرات الأمان طويلة الأمد المتعلقة بالنمو والنضج والتطور الإدراكي والسلوكي عند تناوُل هذه الفئة العمرية لفينيكسور&trade;.</p><p>&nbsp;</p><p>تناول الأدوية الأخرى مع فينيكسور&trade;</p><p>يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. يجب أن يقرر طبيبك ما إذا كان بإمكانك تناول فينيكسور&trade; مع أدوية أخرى أم لا.</p><p>لا تبدأ تناول أي أدوية أو تتوقف عن تناولها قبل مراجعة طبيبك أو الصيدلي، بما في ذلك الأدوية التي اشتريتها بدون وصفة طبية والعلاجات العشبية.</p><p>&bull; يُحظر تناول مثبطات أوكسيداز أحادي الأمين التي تستخدم في علاج الاكتئاب أو مرض باركنسون مع فينيكسور&trade;. أخبر طبيبك إذا كنت قد تناولت هذا النوع من الأدوية خلال الأسبوعين الماضيين. (مثبطات أوكسيداز أحادي الأمين: انظر قسم &quot;ما تحتاج إلى معرفته قبل تناوُل فينيكسور&trade;&quot;).</p><p>&nbsp;</p><p>&bull; متلازمة السيرُوتُونين:</p><p>قد تحدث حالة خطرة مهددة للحياة أو ردود فعل تشبه المتلازمة الخبيثة للدواء المضاد للذهان (انظر قسم &quot;الآثار الجانبية المحتملة&quot;) عند العلاج بفينلافاكسين، خاصة عند تناوله مع أدوية أخرى.</p><p>قد تشمل هذه الأدوية:</p><p>- أدوية التريبتانات (تستخدم في علاج الصداع النصفي).</p><p>- أدوية أخرى لعلاج الاكتئاب، مثل: مثبطات إعادة امتصاص السيروتونين والنورابينفرين، أو مثبطات إعادة امتصاص السيروتونين الانتقائية، أو الأدوية ثلاثية الحلقات، أو أدوية تحتوي على الليثيوم.</p><p>- الأدوية التي تحتوي على لينزوليد، وهو مضاد حيوي (تُستخدم لعلاج العدوى).</p><p>- الأدوية التي تحتوي على موكلوبيميد، وهو مثبط أوكسيداز أحادي الأمين (تُستخدم لعلاج الاكتئاب)</p><p>- الأدوية التي تحتوي على سيبوترامين (تُستخدم لإنقاص الوزن).</p><p>- الأدوية التي تحتوي على ترامادول، أو فينتانيل، أو تابينتادول، أو بيثيدين، أو بينتازوسين (تُستخدم لعلاج الألم الشديد).</p><p>- الأدوية التي تحتوي على ديكستروميثورفان (تُستخدم لعلاج السُّعال).</p><p>- الأدوية التي تحتوي على ميثادون (تُستخدم لعلاج إدمان الأدوية أشباه الأفيونات أو الألم الشديد).</p><p>- الأدوية التي تحتوي على أزرق الميثيلين (تُستخدم لعلاج ارتفاع مستويات الميتهموجلوبين في الدم).</p><p>- المستحضرات التي تحتوي على عشبة سانت جونز (تُسمى أيضًا هايبريكوم برفوراتام، وهي عشبة طبيعية لعلاج الاكتئاب الطفيف).</p><p>- المنتجات التي تحتوي على التربتوفان (تُستخدم لعلاج اضطرابات مثل النوم والاكتئاب)</p><p>- مضادات الذهان (تُستخدم لعلاج مرض له أعراض مثل سماع أصوات أو رؤية أشياء أو الشعور بأشياء ليست موجودة، وتكوين معتقدات خاطئة، وارتياب غير معتاد، وارتباك، وانعزال المرء عمن حوله).</p><p>&nbsp;</p><p>قد تتضمن علامات وأعراض متلازمة السيرُوتُونين مجموعة من الأعراض التالية:</p><p>تململ، هلاوس، فقدان التنسيق الحركي، تسرع ضربات القلب، ارتفاع درجة حرارة الجسم، تغيرات سريعة في ضغط الدم، ردود فعل مفرطة، إسهال، غيبوبة، غثيان، قيء.</p><p>قد تشبه أعراض متلازمة السيرُوتُونين في أشد حالاتها أعراض المتلازمة الخبيثة للدواء المضاد للذهان. قد تتضمن أعراض المتلازمة الخبيثة للدواء المضاد للذهان مزيج من الحمى وتسرع ضربات القلب وتصلب العضلات الشديد وارتباك وزيادة انزيمات العضلات (تظهر في فحص الدم).</p><p>&nbsp;</p><p>إذا كنت تعتقد أنك تعاني من أعراض متلازمة السيرُوتُونين، أخبر طبيبك على الفور، أو اذهب إلى قسم الطوارئ بأقرب مستشفى إليك.</p><p>يجب عليك أن تخبر طبيبك إذا كنت تستخدم أي أدوية تؤثر على نظم قلبك. قد تشمل هذه الأدوية:</p><p>&bull; مضادات اضطراب النظم القلبي، مثل: كوينيدين، أو أميودارون، أو سوتالول، أو دوفيتيليد (تُستخدم لعلاج عدم انتظام نظم القلب)</p><p>&bull; مضادات الذهان، مثل: ثيوريدازين (انظر أيضا &quot;متلازمة السيرُوتُونين: أعلاه)</p><p>&bull; المضادات الحيوية، مثل: إريثروميسين أو موكسيفلوكاسين (تُستخدم في علاج العدوى البكتيرية)</p><p>&bull; مضادات الهيستامين (تُستخدم لعلاج الحساسية)</p><p>&nbsp;</p><p>قد تتفاعل الأدوية التالية مع فينيكسور&trade;، لذا يجب استخدامها بحذر. من المهم جدًّا أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p>&bull; كيتوكونازول (دواء مضاد للفطريات).</p><p>&bull; هالوبيريدول أو ريسبيريدون (لعلاج الحالات النفسية)</p><p>&bull; ميتوبرولول (مُحْصِر مستقبلات بيتا يستخدم لعلاج ارتفاع ضغط الدم ومشاكل القلب)</p><p>&nbsp;</p><p>تناوُل فينيكسور&trade; مع الأغذية والمشروبات والكحوليات</p><p>يجب تناول فينيكسور&trade; مع الطعام (انظر قسم 3 &quot;كيفية تناول فينيكسور&trade;). يجب تجنب المشروبات الكحولية أثناء العلاج بفينيكسور&trade;.</p><p>&nbsp;</p><p>الحمل والرضاعة الطبيعية</p><p>إذا كنتِ حاملًا أو تمارسين الإرضاع الطبيعي أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدليِ قبل تناوُل هذا الدَّواء. يجب عليك ألا تستخدمي فينيكسور&trade; إلا بعد التحدث مع طبيبك بخصوص الفوائد المتوقعة والمخاطر المحتملة على الجنين.</p><p>تأكدي من إخبار ممرضة التوليد و/أو طبيبك بأنك تتناولين فينيكسور&trade;. عند تناوُله أثناء الحمل، قد تُزيد الأدوية المماثلة (مثبطات إعادة امتصاص السيروتونين الانتقائية) من خطر حدوث حالة خطيرة في الأطفال الرضع، تُسَمى ارتفاع ضغط الدَّم الرئوي المستمر للمولود الجديد (PPHN)، مما يجعل الطفل يتنفس بصورة أسرع ويبدو لونه يميل إلى اللون الأزرق. عادة ما تبدأ هذه الأعراض أثناء</p><p>الـ ٤٢ ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلك فيجب عليك الاتصال بممرضة التوليد و/ أو الطبيب فورًا.</p><p>إإذا كنتِ تأخذين هذا الدواء خلال فترة الحمل، قد يصاب طفلك بعرض آخر بالإضافة إلى وجود صعوبة في التنفس، وهو سوء التغذية بعد الولادة. إذا أُصيب طفلك بهذه الأعراض عند ولادته وشعرتِ بالقلق حيال صحة طفلك، اتصلي بطبيبك و/أو ممرضة التوليد الخاصة لطلب الاستشارة.</p><p>يمُرّ فينيكسور&trade; إلى لبن الأم. قد يتعرض الجنين لخطر الإصابة بأثر جانبي. لذلك، يجب أن تتحدثي مع طبيبك في ذلك الأمر، وسيقرر الطبيب ما إذا كان يجب إيقاف الإرضاع الطبيعي أو إيقاف العلاج بهذا الدواء.</p><p>&nbsp;</p><p>القيادة و استخدام الآلات</p><p>يُحظر كل من القيادة أو استخدام أي أدوات أو آلات حتى تتأكد من تأثير هذا الدواء عليك.</p><p>&nbsp;</p><p>معلومات هامة حول بعض مكونات فينيكسور&trade;</p><p>هذه الاقراص تحتوي على اللاكتوز. إذا أخبرك طبيبك أنه لا يمكنك هضم أو تحمل بعض السكريات، أخبر الطبيبك بهذا قبل البدء فى تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>3. كيفية تناول فينيكسور&trade;</p><p>&nbsp;</p><p>تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يجب عليك مراجعة طبيبك أو الصيدلي لك إذا لم تكن متأكدًا من كيفية التناوُل.</p><p>جرعة البدء المعتادة الموصى بها لعلاج الاكتئاب أو اضطراب القلق المعمم واضطراب القلق الاجتماعي</p><p>هي ٥٧ ملجم يوميًّا. يمكن أن يزيد طبيبك الجرعة تدريجيًّا بحد أٌقصى ٥٧٣ ملجم مرة واحدة يوميًا لعلاج الاكتئاب، إذا لزم الأمر ذلك. إذا كنت تخضع لعلاج اضطراب الذعر، سوف يبدأ طبيبك بجرعة أقل</p><p>(٥,٧٣ ملجم) ثم يزيدها تدريجيًّا. الحد الأقصى لجرعة علاج اضطراب القلق المعمم واضطراب القلق الاجتماعي واضطراب الذعر هي ٥٢٢ ملجم يوميًّا.</p><p>تناول فينيكسور&trade; في نفس الوقت تقريبًا من كل يوم، إما في الصباح أو في المساء.</p><p>يجب تناول فينيكسور&trade; مع الطعام.</p><p>إذا كنت تعاني من مشاكل بالكبد أو الكلى، تحدث مع طبيبك؛ إذا إنه قد يُعدِّل الجرعة التي تتناولها.</p><p>يجب ألا تتوقف عن تناوُل هذا الدواء دون التَّحدث إلى طبيبك أولًا (انظر قسم &quot;إذا توقفت عن تناول</p><p>فينيكسور&trade;&quot;).</p><p>&nbsp;</p><p>إذا تناولت كمية أكثر مما ينبغي من فينيكسور&trade;</p><p>اتصل بطبيبك أو الصيدلي فورًا إذا تناولت كمية أكثر من التي وصفها لك طبيبك.</p><p>ويمكن أن تشمل أعراض الجرعة الزائدة سرعة ضربات القلب، وتغير مستوى اليقظة (بدءًا من النعاس إلى غيبوبة)، وعدم وضوح الرؤية، ونوبات تشنج، وقيء.</p><p>&nbsp;</p><p>إذا أغفلت تناول فينيكسور&trade;</p><p>إذا أغفلت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. ومع ذلك، إذا كنت على وشك تناوُل الجرعة التالية، فتجاوز الجرعة التي أغفلتها. لا تتناول جرعة مضاعفة لتعويض تلك التي أغفلتها.</p><p>لا تتناول أكثر من الجرعة اليومية من فينيكسور&trade; والتي تم وصفها لك في اليوم.</p><p>&nbsp;</p><p>إذا توقفت عن تناول فينيكسور&trade;</p><p>لا تتوقف عن تناوُل العلاج أو تقلل الجرعة بدون استشارة طبيبك حتى لو شعرت بتحسن. إذا رأى طبيبك أنك لم تعد بحاجة لفينيكسور&trade;، فقد يطلب منك خفض جرعتك تدريجيًّا قبل إيقاف العلاج تمامًا. ومن المعروف أن الآثار الجانبية تحدث عندما يتوقف الناس عن استخدام هذا الدواء، وخصوصا عند التوقف عن تناول الدواء فجأة أو خفض الجرعة بسرعة كبيرة جدًّا. قد يُصاب بعض المرضى بأعراض مثل تعب، أو دوخة، أو دوار خفيف، أو صداع، أو أرق، أو كوابيس، أو جفاف الفم، أو فقدان الشهية، أو غثيان، أو إسهال، أو عصبية، أو تهيج، أو ارتباك، أو طنين في الأذنين، أو خز أو نادرًا الشعور بصدمات كهربائية، أو ضعف، أو تعرق، أو نوبات صرع، أو أعراض شبيهة بالإنفلونزا.</p><p>سوف يقدم لك طبيبكِ مشورة بخصوص كيفية إيقاف العلاج بفينيكسور&trade; تدريجيًّا. استشر طبيبك إذا أصبت بأي من هذه الأعراض المُتعبة.</p><p>إذا كانت لديك أية أسئلة إضافية متعلقة باستخدام هذا الدواء، فاستشر طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>4. الآثار الجانبية المحتملة</p><p>&nbsp;</p><p>مثله مثل كافة الأدوية، قد يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>إذا حدث أي مما يلي، لا تتناول المزيد من فينيكسور&trade;. أخبر طبيبك على الفور، أو اذهب إلى قسم الطوارئ بأقرب مستشفى إليك:</p><p>غير شائعة (قد تؤثر على ما يصل إلى 1 من بين كل 00١ شخص)</p><p>&bull; تورم في الوجه أو الفم أو اللسان أو الحلق أو اليدين أو القدمين، و/أو طفح جلدي يسبب حكة متزايدة (شرى)، مشاكل في البلع أو في التنفس</p><p>نادرة (قد تُؤثر على ما يصل إلى 1 من بين كل 000١ شخص)</p><p>&bull; ضيق في الصدر، أو أزيز في الصدر، أو مشاكل في البلع أو في التنفس</p><p>&bull; طفح جلدي شديد، أو حكة، أو شرى (بقع مرتفعة من الجلد الأحمر أو الشاحب التي غالبا ما تسبب حكة)</p><p>&nbsp;</p><p>- علامات وأعراض متلازمة السيروتونين والتي قد تشمل أرق، وهلوسة، وفقدان التنسيق الحركي، وتسارع ضربات القلب، وزيادة درجة حرارة الجسم، والتغيرات السريعة في ضغط الدم، وردود الفعل المفرطة، وإسهال، وغيبوبة، وغثيان، وقيء.</p><p>قد تشبه أعراض متلازمة السيرُوتُونين في أشد حالاتها أعراض المتلازمة الخبيثة للدواء المضاد للذهان. قد تتضمن أعراض المتلازمة الخبيثة للدواء المضاد للذهان مزيج من الحمى وتسرع ضربات القلب وتصلب العضلات الشديد وارتباك وزيادة إنزيمات العضلات (تظهر في فحص الدم).</p><p>&bull; علامات تدل على حدوث عدوى خطيرة، مثل: ارتفاع درجة حرارة الجسم، ارتعاش، صداع، تعرق، أعراض تشبه الإنفلونزا. قد يؤدي هذا إلى اضطراب في الدم مما ينجم عنه زيادة خطر حدوث عدوى.</p><p>&bull; طفح جلدي شديد، والذي قد يؤدي إلى تقرح وتقشر شديد في الجلد.</p><p>&bull; ألم وضعف ووهن غير مبررين في العضلات. قد يدل هذا على انحلال الربيدات.</p><p>تتضمن الآثار الجانبية الأخرى التي يجب أن تخبر طبيبك بها (تكرر الآثار الجانبية المذكورة في قائمة &quot;آثار جانبية أخرى قد تحدث&quot; أدناه):</p><p>&bull; سعال وأزيز بالصدر وضيق تنفس قد يكونوا مصحوبين بارتفاع درجة حرارة الجسم</p><p>&bull; براز أسود (قطراني) أو ظهور دم في البراز</p><p>&bull; حكة أو اصفرار الجلد أو العينين أو بول داكن، والتي قد تكون أعراضًا تدل على التهاب الكبد</p><p>&bull; مشاكل في القلب، مثل: تسرع معدل ضربات القلب أو عدم انتظامها أو ارتفاع ضغط الدم</p><p>&bull; مشاكل في العين، مثل عدم وضوح الرؤية أو توسع حدقتي العينين.</p><p>&bull; مشاكل في الأعصاب، مثل دوخة، إبر ودبابيس (وخز)، اضطراب الحركة (تشنجات العضلات أو تصلبها)، نوبات تشنج</p><p>&bull; اضطرابات نفسية، مثل: فرط النشاط والشعور بحماس شديد غير اعتيادي</p><p>&bull; أعراض الانسحاب (انظر قسم &quot;كيفية تناول فينيكسور&trade;، إذا توقفت عن تناول فينيكسور&trade;&quot;).</p><p>&bull; النزيف لفترة طويلة -إذا بجرح نفسك أو اصابتها، فقد يستغرق الجرح مدة أطول قليلًا حتى يتوقف عن النزف.</p><p>&nbsp;</p><p>الآثار الجانبية الأخرى التي قد تحدث</p><p>شائعة جدًّا (قد تُؤثر على أكثر من 1 من بين كل 0١&nbsp;أشخاص)</p><p>&bull; دوخة، صداع، نعاس مفرط</p><p>&bull; أرق</p><p>&bull; غثيان، جفاف الفم، إمساك</p><p>&bull; تعرق (بما في ذلك التعرق ليلًا)</p><p>شائعة (قد تُؤثر على ما يصل إلى 1 من بين كل 0١&nbsp;أشخاص)</p><p>&bull; انخفاض الشهية</p><p>&bull; ارتباك، شعور بالانفصال (أو الغربة) عن نفسك، الافتقار إلى النشوة الجنسية، انخفاض الرغبة الجنسية، تهيُّج، عصبية، أحلام غير طبيعية</p><p>&bull; ارتعاش عضلي، شعور بالتململ أو عدم القدرة على البقاء بوضع ثابت، إبر ودبابيس (وخز)، تغير حاسة التذوق، زيادة التوتر العضلي</p><p>&bull; اضطرابات بصرية، بما في ذلك عدم وضوح الرؤية، اتساع حدقة العين، عدم قدرة العين على تغيير التركيز تلقائيًّا من مسافة بعيدة إلى أخرى قريبة</p><p>&bull; طنين بالأذنين</p><p>&bull; تسارع ضربات القلب، خفقان</p><p>&bull; ارتفاع ضغط الدم، احمرار</p><p>&bull; ضيق في التَّنفس، تثاؤب</p><p>&bull; قيء، إسهال</p><p>&bull; طفح جلدي طفيف، حكة</p><p>&bull; زيادة معدل التبول، عدم القدرة على التبول، صعوبة في إخراج البول</p><p>&bull; اضطرابات الدورة الشهرية، مثل زيادة النزيف أو زيادة نزيف غير منتظم، اضطراب قذف المَنِيّ/ النشوة الجنسية (ذكور)، اضطرابات الانتصاب (عنانة)</p><p>&bull; ضعف (وهن)، تعب، قشعريرة</p><p>&bull; زيادة الوزن، فقدان الوزن</p><p>&bull; ارتفاع الكوليسترول</p><p>غير شائعة (قد تؤثر على ما يصل إلى 1 من بين كل 00١ شخص)</p><p>&bull; فرط النشاط، الأفكار المتسارعة وانخفاض الحاجة إلى النوم (هوس)</p><p>&bull; هلاوس، شعور بالانفصال (أو الغربة) عن الواقع، اضطراب النشوة الجنسية، فقدان الشعور أو الإحساس، الشعور بفرط التحمس، الضغط على الأسنان</p><p>&bull; إغماء، حركات لا إرادية في العضلات، ضعف التنسيق الحركي والتوازن الحركي</p><p>&bull; الشعور بالدوار (خاصة عند الوقوف بسرعة كبيرة جدا)، انخفاض ضغط الدم</p><p>&bull; تقيُؤ دم أو براز قطراني أسود أو ظهور دم في البراز، مما قد يدل على حدوث نزيف داخلي.</p><p>&bull; حساسية تجاه أشعة الشمس، تكدُّم، تساقط غير طبيعي للشعر</p><p>&bull; عدم القدرة على التحكم في التبوُّل</p><p>&bull; تصلب العضلات أو تشنجها وحركات لا إرادية في العضلات</p><p>&bull; تغيرات طفيفة في مستويات إنزيمات الكبد في الدم</p><p>نادرة (قد تُؤثر على ما يصل إلى 1 من بين كل 000١ شخص)</p><p>&bull; نوبات تشنُّج</p><p>&bull; سعال وأزيز بالصدر وضيق تنفس قد يكونوا مصحوبين بارتفاع درجة حرارة الجسم</p><p>&bull; توهان وارتباك عادة ما يكونا مصحوبان بهلوسة (هذيان)</p><p>&bull; امتصاص زائد للماء (المعروفة باسم متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول)</p><p>&bull; انخفاض مستويات الصوديوم في الدم</p><p>&bull; ألم شديد في العين وانخفاض جودة الرؤية أو عدم وضوح الرؤية</p><p>&bull; ضربات قلب غير طبيعية أو سريعة أو غير منتظمة، مما قد يؤدي إلى حدوث إغماء</p><p>&bull; آلام شديدة في البطن أو الظهر (قد تدل على وجود مشكلة خطيرة في الأمعاء، أو الكبد أو البنكرياس)</p><p>&bull; حكة أو اصفرار الجلد أو العينين أو بول داكن أو أعراض تشبه الإنفلونزا، والتي قد تكون أعراضًا تدل على الإصابة بالتهاب الكبد</p><p>نادرة جدًّا (قد تُؤثر على ما يصل إلى 1 من بين كل 000,0١ شخص)</p><p>&bull; طول مدة النزف، مما قد يدل على نقص الصفائح الدَّموية في دمك والذي قد يؤدي إلى زيادة خطر التكدم أو النزف</p><p>&bull; إفراز غير طبيعي للبن الثدي</p><p>&bull; نزيف غير متوقع، مثل: نزيف اللثة، أو دم في البول أو في القيء، أو ظهور كدمات غير متوقعة أو تكسر الأوعية الدموية</p><p>معدل التكرار غير معروف (لا يمكن تقديره من واقع البيانات المتاحة)</p><p>&bull; التفكير في الانتحار وسلوكيات انتحارية، قد تم الإبلاغ عن حالات فكرت في الانتحار أو قامت بسلوكيات انتحارية أثناء العلاج بفينلافاكسين أو في مرحلة مبكرة بعد توقف العلاج (انظر قسم 2 &quot;ما تحتاج إلى معرفته قبل تناوُل فينيكسور&trade;&quot;)</p><p>&bull; عدوانية</p><p>&bull; دوار</p><p>&bull; قد يسبب فينيكسور&trade; آثارًا جانبية غير مرغوب بها والتي قد لا تدرك وجودها، مثل: ارتفاع ضغط الدم أو ضربات قلب غير طبيعية، وتغيرات بسيطة في مستويات إنزيمات الكبد والصوديوم والكوليسترول في الدم. وأكثر ندرة، قد يقلل فينيكسور&trade; من وظيفة الصفائح الدموية في الدم، مما يؤدي إلى ارتفاع خطر الإصابة بكدمات أو نزيف.</p><p>لذلك، قد يطلب منك طبيبك أن تجري فحوصات الدم بين الحين والآخر، خاصة إذا كنت تتناول فينيكسور&trade; لمدة طويلة.</p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p>&nbsp;إذا أصبت بأيَّة آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي. بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>5. كيفية تخزين فينيكسور&trade;</p><p>&nbsp;</p><p>يحفظ بعيدًا عن متناول و مرأى الأطفال.</p><p>لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة.</p><p>يحفظ في درجة حرارة لا تزيد عن ٠3 درجة مئوية.</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>6. معلومات إضافية</p><p>&nbsp;</p><p>على ماذا يحتوي فينيكسور&trade;؟</p><p>المادة الفعالة هي فينلافاكسين هيدروكلوريد.</p><p>يحتوي كل قرص على ٨٢,٨٢ ملجم، ٢٤,٢٤ ملجم، ٦٥,٦٥ ملجم، ٤٨,٤٨ ملجم من فينلافاكسين هيدروكلوريد ، مما يعادل ٥٢ ملجم، ٥,٧٣ ملجم، ٠٥ ملجم، ٥٧ ملجم من فينلافاكسين، تباعًا.</p><p>المكونات الأخرى هي: مونوهيدرات اللاكتوز، وسليلوز دقيق التَبلّور، جليكولات نشا الصوديوم، أكسيد الحديد الأصفر، ثاني أكسيد السيليكون الغروي و ستيرات الماغنسيوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>ما هو شكل فينيكسور&trade;؟ و ما هي محتويات العبوة؟</p><p>٥٢ ملجم: أقراص لونها أصفر شاحب يميل إلى الصفرة، مبقعة بدوائر، محدبة الوجهين، محفور على أحد جانبيها &quot;JP&quot; وعلى الجانب الآخر &quot;AN&quot;.</p><p>٥,٧٣ ملجم: أقراص لونها أصفر شاحب يميل إلى الصفرة، مبقعة بدوائر، محدبة الوجهين، محفور على أحد جانبيها &quot;AP&quot; وعلى الجانب الآخر &quot;JP&quot;.</p><p>٠٥ ملجم: أقراص لونها أصفر شاحب يميل إلى الصفرة، مبقعة بدوائر، محفور على أحد جانبيها &quot;JP&quot; وعلى الجانب الآخر &quot;٤٥١&quot;.</p><p>٥٧ ملجم: أقراص لونها أصفر شاحب يميل إلى الصفرة، مبقعة بدوائر، محدبة الوجهين، محفور على أحد جانبيها &quot;٥٥١&quot; وعلى الجانب الآخر &quot;JP&quot; بجانب خط فاصل للكسر.</p><p>أقراص فينيكسور&trade; متوفرة في أقراص ٥٢ ملجم، و٥,٧٣ ملجم، و ٠٥ ملجم، و٥٧ ملجم في علب تحتوي كل علبة على ٠٣ قرص.</p><p>&nbsp;</p><p>قد لا يتم تسويق جميع العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>اسم وعنوان مالك رخصة التسويق و المصنع:</p><p>شركة مصنع جمجوم للأدوية، جدة، المملكة العربية السعودية.</p><p>هاتف: 6081111-12-966+&nbsp;&nbsp; فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني: www.jamjoompharma.com</p><p>&nbsp;</p><p>للإبلاغ عن أي أثار جانبيه:</p><p>&nbsp;</p><p>&bull; المملكة العربية السعودية:</p><p>- المركز الوطني للتيقظ و السلامة الدوائية</p><p>&nbsp;&nbsp; o فاكس: 7662-205-11-966+</p><p>&nbsp;&nbsp; o للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 2038222-11-966+</p><p>&nbsp;&nbsp;&nbsp;&nbsp; تحويلة: 2317-2356-2353-2354-2334-2340</p><p>&nbsp;&nbsp; o الهاتف المجاني: 8002490000&nbsp;&nbsp;</p><p>&nbsp;&nbsp; o بريد إلكتروني: npc.drug@sfda.gov.sa</p><p>&nbsp;&nbsp; o الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull; دول الخليج الأخرى:</p><p>- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة في 0٣  /2017. رقم النسخة 01
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fenixor™ 50 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains Venlafaxine Hydrochloride equivalent to 50 mg Venlafaxine.
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
Pale yellow to yellow colored, mottled, round, biconvex tablets debossed with 'JP' on one side and
'154' on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive episodes.<br />&bull; For prevention of recurrence of major depressive episodes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Major depressive episodes<br />The recommended starting dose of immediate-release venlafaxine is 75mg/day in two or three divided<br />doses taken with food. Patients not responding to the initial 75mg/day dose may benefit from dose<br />increases up to a maximum dose of 375mg/day. Dosage increases can be made at intervals of 2 weeks<br />or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent<br />intervals, but not less than 4 days.<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a<br />clinical evaluation (see section 4.4). The lowest effective dose should be maintained.<br />Patients should be treated for a sufficient period of time, usually several months or longer. Treatment<br />should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be</p><p>appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases,<br />the recommended dose in prevention of recurrence of MDE is the same as the one used during the<br />current episode.<br />Antidepressive medicinal products should continue for at least six months following remission.<br />Use in elderly patients<br />No specific dose adjustments of venlafaxine are considered necessary based on patient age alone.<br />However, caution should be exercised in treating the elderly (e.g., due to the possibility of renal<br />impairment, the potential for changes in neurotransmitter sensitivity and affinity occurring with<br />aging). The lowest effective dose should always be used, and patients should be carefully monitored<br />when an increase in the dose is required.<br />Use in children and adolescents under the age of 18 years<br />Venlafaxine is not recommended for use in children and adolescents.<br />Controlled clinical studies in children and adolescents with major depressive disorder failed to<br />demonstrate efficacy and do not support the use of venlafaxine in these patients (see sections 4.4 and<br />4.8).<br />The efficacy and safety of venlafaxine for other indications in children and adolescents under the age<br />of 18 have not been established.<br />Use in patients with hepatic impairment<br />In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be<br />considered. However, due to inter-individual variability in clearance, individualisation of dosage may<br />be desirable.<br />There are limited data in patients with severe hepatic impairment. Caution is advised, and a dose<br />reduction by more than 50% should be considered. The potential benefit should be weighed against<br />the risk in the treatment of patients with severe hepatic impairment.</p><p>Use in patients with renal impairment<br />Although no change in dosage is necessary for patients with glomerular filtration rate (GFR) between<br />30-70ml/minute, caution is advised. For patients that require haemodialysis and in patients with<br />severe renal impairment (GFR &lt; 30ml/min), the dose should be reduced by 50%. Because of interindividual<br />variability in clearance in these patients, individualisation of dosage may be desirable.<br />Withdrawal symptoms seen on discontinuation of venlafaxine<br />Abrupt discontinuation should be avoided. When stopping treatment with venlafaxine, the dose<br />should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of<br />withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease<br />in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may<br />be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual<br />rate.<br />For oral use.<br />It is recommended that venlafaxine immediate-release tablets be taken with food, at approximately<br />the same time each day.<br />Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine<br />prolonged-release capsules at the nearest equivalent daily dosage. For example, venlafaxine<br />immediate-release tablets 37.5mg twice daily may be switched to venlafaxine prolonged-release<br />capsules 75mg once daily. Individual dosage adjustments may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to venlafaxine or to any of the excipients.
• Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated
due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia.
• Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an
irreversible MAOI.
• Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible
MAOI (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Suicide/suicidal thoughts or clinical worsening:<br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suiciderelated<br />events).<br />This risk persists until significant remission occurs. As improvement may not occur during the first<br />few weeks or more of treatment, patients should be closely monitored until such improvement occurs.<br />It is general clinical experience that the risk of suicide may increase in the early stages of recovery.<br />Other psychiatric conditions for which venlafaxine is prescribed can also be associated with an<br />increased risk of suicide related events. In addition, these conditions may be co-morbid with major<br />depressive disorder. The same precautions observed when treating patients with major depressive<br />disorder should therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal<br />ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or<br />suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebocontrolled<br />clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed<br />an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than<br />25 years old.<br />Close supervision of patients and in particular those at high risk should accompany drug therapy<br />especially in early treatment and following dose changes. Patients (and caregivers of patients) should<br />be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and<br />unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>&bull; Use in children and adolescents under 18 years of age.<br />Venlafaxine Tablets should not be used in the treatment of children and adolescents under the age of<br />18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility<br />(predominantly aggression, oppositional behaviour and anger) were more frequently observed in<br />clinical trials among children and adolescents treated with antidepressants compared to those treated<br />with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should<br />be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in<br />children and adolescents concerning growth, maturation and cognitive and behavioural development<br />are lacking.<br />&bull; Serotonin syndrome<br />As with other serotonergic agents, the development of a potentially lifethreatening condition<br />serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions, serotonin syndrome,<br />a potentially life-threatening condition, may occur with venlafaxine treatment, particularly with<br />concomitant use of other agents that may affect the serotonergic neurotransmitter system (including<br />triptans, SSRIs, SNRIs, lithium, sibutramine, St.John&#39;s Wort [Hypericum perforatum], fentanyl and<br />its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with<br />medicinal agents that impair metabolism of serotonin such as MAOIs e.g. methylene blue, with<br />serotonin precursors (such as tryptophan supplements) or with antipsychotics or other dopamine<br />antagonists (see sections 4.3 and 4.5).<br />Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations,<br />coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular<br />aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea,<br />vomiting, diarrhoea). Serotonin syndrome in its most severe form, can resemble NMS, which includes<br />hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs and<br />mental status changes.<br />If concomitant treatment with venlafaxine and other agents that may affect the serotonergic and/or<br />dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is</p><p>advised, particularly during treatment initiation and dose increases. The concomitant use of<br />venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended.<br />&bull; Narrow-angle glaucoma<br />Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised<br />intraocular pressure or patients at risk for acute narrow-angle glaucoma (angle-closure glaucoma) be<br />closely monitored.<br />&bull; Blood pressure<br />Dose-related increases in blood pressure have been commonly reported with venlafaxine. In some<br />cases, severely elevated blood pressure requiring immediate treatment has been reported in<br />postmarketing experience. All patients should be carefully screened for high blood pressure and<br />preexisting hypertension should be controlled before initation of treatment. Blood pressure should be<br />reviewed periodically, after initiation of treatment and after dose increases. Caution should be<br />exercised in patients whose underlying conditions might be compromised by increases in blood<br />pressure, e.g., those with impaired cardiac function.<br />&bull; Heart rate<br />Increases in heart rate can occur, particularly with higher doses. Caution should be exercised in<br />patients whose underlying conditions might be compromised by increases in heart rate.<br />&bull; Cardiac disease and risk of arrhythmia<br />Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or<br />unstable heart disease. Therefore, it should be used with caution in these patients. In postmarketing<br />experience, cases of QTc prolongation, Torsade de Pointes (TdP), ventricular tachycardia, and fatal<br />cardiac arrhythmias have been reported with the use of venlafaxine, especially in overdose or in<br />patients with other risk factors for QTc prolongation/TdP. The balance of risks and benefits should<br />be considered before prescribing venlafaxine to patients at high risk of serious cardiac arrhythmia or<br />QTc prolongation.</p><p>&bull; Convulsions<br />Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be<br />introduced with caution in patients with a history of convulsions, and concerned patients should be<br />closely monitored. Treatment should be discontinued in any patient who develops seizures.<br />&bull; Hyponatraemia<br />Cases of hyponatraemia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH)<br />secretion may occur with venlafaxine. This has most frequently been reported in volume-depleted or<br />dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise<br />volume-depleted may be at greater risk for this event.<br />&bull; Abnormal bleeding<br />Medicinal products that inhibit serotonin uptake may lead to reduced platelet function. The risk of<br />skin and mucous membrane bleeding, including gastrointestinal haemorrhage, may be increased in<br />patients taking venlafaxine. As with other serotonin-reuptake inhibitors, venlafaxine should be used<br />cautiously in patients predisposed to bleeding, including patients on anticoagulants and platelet<br />inhibitors.<br />&bull; Serum cholesterol<br />Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated<br />patients and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled<br />clinical trials. Measurement of serum cholesterol levels should be considered during long-term<br />treatment.<br />&bull; Co-administration with weight loss agents<br />The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including<br />phentermine, have not been established.</p><p>Co-administration of venlafaxine and weight loss agents is not recommended. Venlafaxine is not<br />indicated for weight loss alone or in combination with other products.<br />&bull; Mania/hypomania<br />Mania/hypomania may occur in a small proportion of patients with mood disorders who have received<br />antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used<br />cautiously in patients with a history or family history of bipolar disorder.<br />&bull; Aggression<br />Aggression may occur in a small number of patients who have received antidepressants, including<br />venlafaxine. This has been reported under initiation, dose changes and discontinuation of treatment.<br />As with other antidepressants, venlafaxine should be used cautiously in patients with a history of<br />aggression.<br />&bull; Discontinuation of treatment<br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is<br />abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation (tapering<br />and post-tapering) occurred in approximately 31% of patients treated with venlafaxine and 17% of<br />patients taking placebo.<br />The risk of withdrawal symptoms may be dependent on several factors, including the duration and<br />dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including<br />paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety,<br />nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally,<br />these symptoms are mild to moderate; however, in some patients they may be severe in intensity.<br />They usually occur within the first few days of discontinuing treatment, but there have been very rare<br />reports of such symptoms in patients who have inadvertently missed a dose. Generally, these<br />symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may<br />be prolonged (2-3 months or more). It is therefore advised that venlafaxine should be gradually</p><p>tapered when discontinuing treatment over a period of several weeks or months, according to the<br />patient&#39;s needs (see section 4.2).<br />&bull; Akathisia/psychomotor restlessness<br />The use of venlafaxine has been associated with the development of akathisia, characterised by a<br />subjectively unpleasant or distressing restlessness and need to move often accompanied by an<br />inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In<br />patients who develop these symptoms, increasing the dose may be detrimental.<br />&bull; Dry mouth<br />Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of<br />caries, and patients should be advised upon the importance of dental hygiene.<br />&bull; Diabetes<br />In patients with diabetes, treatment with an SSRI or venlafaxine may alter glycaemic control. Insulin<br />and/or antidiabetic dosage may need to be adjusted.<br />&bull; Excipients of known effect<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.<br />Drug-Laboratory Test Interactions<br />False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have<br />been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests.<br />False positive test results may be expected for several days following discontinuation of<br />venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will<br />distinguish venlafaxine from PCP and amphetamine.</p><p>Lactose intolerance<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Monoamine Oxidase Inhibitors (MAOI)<br />Irreversible non-selective MAOIs<br />Venlafaxine must not be used in combination with irreversible non-selective MAOIs. Venlafaxine<br />must not be initiated for at least 14 days after discontinuation of treatment with an irreversible nonselective<br />MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with<br />an irreversible non-selective MAOI (see sections 4.3 and 4.4).<br />Reversible, selective MAO-A inhibitor (moclobemide)<br />Due to the risk of serotonin syndrome, the combination of venlafaxine with a reversible and selective<br />MAOI, such as moclobemide, is not recommended. Following treatment with a reversible MAOinhibitor,<br />a shorter withdrawal period than 14 days may be used before initiation of venlafaxine<br />treatment. It is recommended that venlafaxine should be discontinued for at least 7 days before<br />starting treatment with a reversible MAOI (see section 4.4).<br />Reversible, non-selective MAOI (linezolid)<br />The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to<br />patients treated with venlafaxine (see section 4.4).<br />Severe adverse reactions have been reported in patients who have recently been discontinued from<br />an MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to<br />initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea,<br />vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant<br />syndrome, seizures, and death.</p><p>Serotonin syndrome<br />As with other serotonergic agents, serotonin syndrome may occur with venlafaxine treatment,<br />particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter<br />system (including triptans, SSRIs, SNRIs, lithium, sibutramine, tramadol, or St. John&#39;s Wort<br />[Hypericum perforatum]), with medicinal agents which impair metabolism of serotonin (including<br />MAOIs), or with serotonin precursors (such as tryptophan supplements).<br />If concomitant treatment of venlafaxine with an SSRI, an SNRI or a serotonin receptor agonist<br />(triptan) is clinically warranted, careful observation of the patient is advised, particularly during<br />treatment initiation and dose increases. The concomitant use of venlafaxine with serotonin precursors<br />(such as tryptophan supplements) is not recommended (see section 4.4).<br />CNS-active substances<br />The risk of using venlafaxine in combination with other CNS-active substances has not been<br />systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination<br />with other CNS-active substances.<br />Ethanol<br />Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by<br />ethanol. However, as with all CNS-active substances, patients should be advised to avoid alcohol<br />consumption.<br />Drugs that Prolong the QT Interval<br />The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with<br />concomitant use of other medicinal products, which prolong the QTc interval. Coadministration of<br />such medicinal products should be avoided (see section 4.4).<br />Relevant classes include:<br />&bull; class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol, dofetilide)<br />&bull; Some antipsychotics (e.g. thioridazine)</p><p>Some macrolides (e.g. erythromycin)<br />&bull; Some antihistamines<br />&bull; Some quinolone antibiotics (e.g. moxifloxacin) The above list is not exhaustive and other individual<br />medicinal products known to significantly increase QT interval should be avoided.<br />Effect of other medicinal products on venlafaxine<br />Ketoconazole (CYP3A4 inhibitor)<br />A pharmacokinetic study with ketoconazole in CYP2D6 extensive (EM) and poor metabolisers (PM)<br />resulted in higher AUC of venlafaxine (70% and 21% in CYP2D6 PM and EM subjects, respectively)<br />and O-desmethylvenlafaxine (33% and 23% in CYP2D6 PM and EM subjects, respectively)<br />following administration of ketoconazole. Concomitant use of CYP3A4 inhibitors (e.g., atazanavir,<br />clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir,<br />ritonavir, saquinavir, telithromycin) and venlafaxine may increase levels of venlafaxine and Odesmethylvenlafaxine.<br />Therefore, caution is advised if a patient&#39;s therapy includes a CYP3A4<br />inhibitor and venlafaxine concomitantly.<br />Oral contraceptives<br />In post-marketing experience unintended pregnancies have been reported in subjects taking oral<br />contraceptives while on venlafaxine. There is no clear evidence these pregnancies were a result of<br />drug interaction with venlafaxine. No interaction study with hormonal contraceptives has been<br />performed.<br />Effect of venlafaxine on other medicinal products<br />Lithium<br />Serotonin syndrome may occur with the concomitant use of venlafaxine and lithium (see Serotonin<br />syndrome).<br />Diazepam<br />Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its<br />active metabolite, desmethyldiazepam. Diazepam does not appear to affect the pharmacokinetics of</p><p>either venlafaxine or O-desmethylvenlafaxine. It is unknown whether a pharmacokinetic and/or<br />pharmacodynamic interaction with other benzodiazepines exists.<br />Imipramine<br />Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. There was a<br />dose-dependent increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold when venlafaxine 75mg to<br />150mg daily was administered. Imipramine did not affect the pharmacokinetics of venlafaxine and<br />O-desmethylvenlafaxine. The clinical significance of this interaction is unknown. Caution should be<br />exercised with co-administration of venlafaxine and imipramine.<br />Haloperidol<br />A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70%<br />increase in AUC, an 88% increase in Cmax, but no change in half-life for haloperidol. This should be<br />taken into account in patients treated with haloperidol and venlafaxine concomitantly. The clinical<br />significance of this interaction is unknown.<br />Risperidone<br />Venlafaxine increased the risperidone AUC by 50%, but did not significantly alter the<br />pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). The<br />clinical significance of this interaction is unknown.<br />Metoprolol<br />Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic<br />interaction study for both medicinal products resulted in an increase of plasma concentrations of<br />metoprolol by approximately 30-40% without altering the plasma concentrations of its active<br />metabolite, &alpha;-hydroxymetoprolol. The clinical relevance of this finding in hypertensive patients is<br />unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite,<br />O-desmethylvenlafaxine. Caution should be exercised with co-administration of venlafaxine and<br />metoprolol.<br />Indinavir</p><p>A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in<br />Cmax for indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and Odesmethylvenlafaxine.<br />The clinical significance of this interaction is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of venlafaxine in pregnant women.<br />Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans<br />is unknown. Venlafaxine must only be administered to pregnant women if the expected benefits<br />outweigh any possible risk.<br />As with other serotonin reuptake inhibitors (SSRIs/SNRIs), discontinuation symptoms may occur in<br />the newborns if venlafaxine is used until or shortly before birth. Some newborns exposed to<br />venlafaxine late in the third trimester have developed complications requiring tube-feeding,<br />respiratory support or prolonged hospitalisation. Such complications can arise immediately upon<br />delivery.<br />The following symptoms may be observed in neonates if the mother has used an SSRI/SNRI late in<br />pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping.<br />These symptoms may be due to either serotonergic effects or exposure symptoms. In the majority of<br />cases, these complications are observed immediately or within 24 hours after partus.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late<br />pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN).<br />Although no studies have investigated an association of PPHN to SNRI treatment, this potential risk<br />cannot be ruled out with venlafaxine taking into account the related mechanism of action (inhibition<br />of the re-uptake of serotonin).<br />Lactation<br />Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. There<br />have been post-marketing reports of breast-fed infants who experienced crying, irritability, and</p><p>abnormal sleep patterns. Symptoms consistent with venlafaxine drug discontinuation have also been<br />reported after stopping breast-feeding. A risk to the suckling child cannot be excluded. Therefore, a<br />decision to continue/discontinue breast-feeding or to continue/discontinue therapy with venlafaxine<br />should be made, taking into account the benefit of breast-feeding to the child and the benefit of<br />venlafaxine therapy to the woman.<br />Fertility<br />Reduced fertility was observed in a study in which both male and female rats were exposed to Odesmethylvenlafaxine.<br />The human relevance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any psychoactive medicinal product may impair judgment, thinking, and motor skills. Therefore, any<br />patient receiving venlafaxine should be cautioned about their ability to drive or operate hazardous<br />machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly (&gt;1/10) reported adverse reactions in clinical studies were nausea, dry mouth,<br />headache and sweating (including night sweats).<br />Adverse reactions are listed below by system organ class and frequency.<br />Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000<br />to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), not known (cannot be estimated from the available data).</p><p><img alt="" width="978" height="270" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAA9IAAAEOCAIAAADqkrj0AAAABGdBTUEAALGPC/xhBQAAACBjSFJNAAB6JgAAgIQAAPoAAACA6AAAdTAAAOpgAAA6mAAAF3CculE8AAAAAXNSR0IArs4c6QAAAAlwSFlzAAAUwwAAFJwBKFMM2QAAACF0RVh0Q3JlYXRpb24gVGltZQAyMDIwOjA2OjIyIDE0OjI3OjUy1ehGmQAAJddJREFUeF7t3e2W4zaSreHOvm7/9HV3Ttjbs1c4AIKQ+CGSep+FlQcMBEASVBWjNOk+P7+/v/8BAAAAcKT//vP/AgAAADgMZTcAAABwOMpuAAAA4HCU3QAAAMDhKLsBAACAw1F2AwAAAIej7AYAAAAOR9kNAAAAHI6yGwAAADjcP/+/VP7xxx86BgAAALA7vu0GAAAADkfZDQAAABzuX79k8ueff/4dBCo+IZ/iXwBj82+BPynPwHP8IDYfTxWf7V2/7f79oV233VS5i483AACAt/BLJgAAAMDhKLsBAACAw1F2AwAAAIej7AYAAAAOR9kNAAAAHO6Qsvvnv/9qDj5Pvk01HKFscrRsMAQAAHAR+xcprnt+//dPO6gY+myB5ZvybUbLcexIe2vtoSNlCAAA4CJ2rhBdcebq53mVUC64M0eovHc38ymayQEAAPiIk8rD3euhD9a1k6em8gYAAIAdVRseWnReoaId/EOC71wP4o1tPwARYdsBAMCVHVjARiWUy6NcM+XWBktEfSv9fCgKlqESLIfdSNd4tFCyly2HmYOlWYlHy0q8HH6z7laUYLfvSAkCAAC8Z+c6ov3GsS1Wco770VFfPzVFwfH0fOhzOe65JS1P1KwS2VF76kKn0wV41P18eQ4qbg4GJ/vwkfJ96ZaLCCrHu+EpObnM7fajo34eBQAAeMn+RVm3NHHFI87J8VIA2au1Tskvpw7tgq+e4m06UT5de3lS4ktprdPu5SNevbuSv/RhyGnu5+Tov3rqq/v9of3TLqVcG21ju51y/VdoeFvZSdrG9gjT1dwrokBpa5T5wtFiimbNVDxvrP9B8zWcNlP53hBYbEi7mW/s0vwTAQAAeMOBRZyLRcvFkIcULMVT7r9aQkW+2pP4jsqWfqHyyRnTvs1kZuMPJwAAwBt2Lk7b+ubteiVPfKlyioml7eil1WaSl3Jy3Pe+7718g9ix0gAAAD5i57I7zFfeji+V1Feukwb/DJj/F4LoHmOWmiPi1S67FR8Um3PQtnhZ7z8AAMAWV6kpSvGUa52NddXuZdPk9cxftmrH3DD29ha992HgiQAAgO0OKbujuMn1jftt+TIoaOYrJGV6qXLqI2omrRmLl4t0ZP6kZYWx9oxfbmmfd/kwvJT8APp05eY4zpQfgZstxfEk5Sm3DTdSnl20bDC0UVlZzUo8Gs6x/05HsaKWn6UiS7pD7QrmvkZ9GB31PTFnmvozkYH2XJriuOWlcj/zCrlJvgUtniOlE9RvIw9TNrnljYrbV2v3LaxuzuqJHkD7E7RpajmOM3n/ZemwxPEk5eHq0C3wZ/NG/NS6PDpO6xp/BsqCg8MyhEPt/Ae3fajvPU5NGazw6lAOKj4TWVWmRGutJizxn6h2bon40ME28jwz99XdhBzM8e+UP2YZmwNck/9gUnnf1EUenC6Dv+dP9uGHH0/9yx85n/jL+oYPp//253MIAIfKf81ur7w3rqAXHH/zn+8DZXc8bDUEf/TbhvN954dz8GHjcwgAe9nrb9SNLykVHvgIit/P6/754U8Fjjb5F3f7OYyJbkUZKofdSCjBctiNFEsJJV4OH6PcVzks8mibMD9UDruRUILlsBsplhJKvBx+obwDalaCuZ853g5hL/4bdXWTlx5HPmxHx5Q/qC6UoNYeFkujOa6hEokmJahW4g/zgRvKnzkqS+1A/oSpsTMfwYdzTB/OEJuTP7qWN0176IgyS0TemyVKCM5xJHhWiOBgnVubvM3o67Cb0I46Ip4SIl4WaSPy3ixRQnCOI8GzQgQH6zxMuwPaFu1Adx8cCcostELwdM/FcZY2ufs4nJwfnxNmeM2BPBr5eX1fQPD1OMGRkBeRvE5wX50yGuvkiJd9hs/cjTY07/I3827k9hy/P5va6VYeQbm8V9sjeHPGH9R2dJwvG2cNkmfWeYDV2xwnzOxkaEdXzxs2zhokz6xzXypo3KS9ZQ+NaWJ3x0pwckG8Ku/zYJOd1n1Yr/KJ5h/r6nkHVzh5zXExb8+9qV3/VP38frhdWbnU8xuwzeAv6/m/x/d1wUu6rHZD4t2mFni4V+bHJOUwKKJgbM7k/niRb9vPKyhPMDvok5/PuPGJv3qFCuahjRdwa1986wAA3M1SyRJxDQ1KujGtsLQ+DnLahu9Yec9oP4clEtfw9mf1vvjjBXypL/z7Drivcc3kyJY/1zG3NBznI9ubT3pauY+MXQe+HX/5ArewVDPtUnPjfB+vvI/mc8VHtJy3jXwJ3rfA98p/Jy6ZeaN/6m/PC17SXgbX/97rylO6z/qCO3nBS7qCM+998NcC9tI+0BM++V7nvUe85Qr3uoX7evifqvhIlea4fpY4zpF3Xs1xnGzw968eTfu35AWf1wUvaS/ljna5wcF2DYY+5YKXdBHdDYngqxvV/Usg+lRIn+XHsfpAX33iWcx9e/r8FcIeu1X+JMVfHG45Hvg75XwzzwUnK0/BzXErmTkiCor6x0VkfEntrDZyWeXW1PLdWb4R9dtIyBMjGC1HvLKGckS8TlD/uIiML6md1UZuKi6+3Es+LA8lWt4TbVHZpTw9981TYlTNK2Aj7WfuFO1Wl8eRI+K+EvKQea7kwxwXj+ahpUjw9UREQUcKBfNQGwntWdrIMzzoVhI/ofJc47BEcCaey5XpKeS2ZJCThzR6XCRbGspxDbWRi5u54DanjchS3AajeUijx0WypaEc11AbualyI2pZO5T7kiPuO9I1k4NX5V1d2thufDxrPBpygttgKFo71I3YUrxoR7uR3LqRZ3hg2b1U2+GzeC4AAOCbPbDslkFtR9n3QTwXAADwnZ5Wdk/+AtBMhRdLlZbl4PzQ15rch/a5eDPbFcpQOexGQgmWw26kWEoo8XIIAAC+HBVBh0qlKAHdHM8dDZWiajCEl8Tu5c3MEVFQIu40HbYReW+WKCE4x5HgWSGCg3UAAMAXohxYNFkq5WKrGAxhkvdwvJnt6Mzmb5w1SJ5ZBwAAfBXK7o6omdRC/jqz8FBbYw2GMGNpz8Ng6FAXvKRNfn5p/7RLKddG29hup1z/FRreVnaStrE9wh3rhZNELaVyqi2dc6SUXIMhAAAAfK2nFYZ7fbvsinlpwVJe5wp7MPS19nouAAAAN/XYknBLseu542IxRpcSBkNfjn+EAACA7/TAIsj17qDC21j85emlvB4MfbmXnstg6z61qxe8JAAAcCPbys+rGlR4EYk2Xycpv9UNymDoy73xXJx5nV294CUBAIDre2zhEAWcariojXJzXEOW+zlB+e2UiERfTYc2GELshjbEW6TmuJXMHBEFRf3jIjK+pHZWGwEAAF/r4bWAqqLcspkhyxH/zEEZDMHy/qgtGeTkIY0eF8mWhnJcQ20EAAB8Lb6CAwAAAA5H2Q0AAAAcjrIbAAAAOBxlNwAAAHA4ym4AAADgcM8qu39+r9u+VtmHL28AAOBb8W03AAAAcLif39+/voH7448/dAwAAABgd3zbDQAAABzuX992//nnn38HgYpPyKf4/xLF5t8Cf1Kegef4QWw+nio+23zbDQAAAByOshsAAFzP7w+N9lq7PMpuAAAA4HCU3QAAAMDhKLsBAACAw1F2AwAAAIej7AYAALf389+/2nVc7Xpu4fGbxicCAABclOqwmXYdV7seXAefCwAAcGm///unDQ6v4yLXc8fS/2qPcneU3QAA4LoGddizSzQ8D2U3AADAo/BbLtfEYwEAABe1+n12N0G/Xd2Wng62CY7koORgm9NGCid0c8ajoZuQg914Pmw5rR110Ak6zPLQeLTIwW5OGxEnLyXcxZ2vHQAAIFFZFrW4ynGXaLlcU0LmKZ6lZHfc90QdKuJZLSd0c9rR1QTRoTruB/WXRmXppO6oX3JEOXlIQVN/aWLul5yckOVk5St4U7e9cAAAgH/LxVmW4+o4oqrOSt+H7reRgTbBJePgvFISCg29WoDO32zRPVGbFsoimhj9HHffusHWTM6VUXYDAIAvNagmX61oV+WScfW8bUKMrhadMWuQs3rSrtWTmq/cDQVbAgAAcD+rFfPu4oy5Cu+eWjm5bVFWuHspT9kNAACAWfomO9rGknre+Wc8CGU3AADALakMjXpUP0+oSnWuONGZNXc484zHoewGAADAOlfAA8qxcviqmTPeCGU3AAD4UqrnuqXh7qVeriBXz9tNGOTHkDoDqyftUv7q4l3dc30z9gMAAHy7XCDOlLCTSt3ZLrt63gi6vaedmCPRH19Vy6NL60RfLeyykz6ROyGf5S5udbEAAOAr5QKrFFtlqO245YhFXajS0GmlfHR/puP+YFmZScic32rjirTLepGlk0oEc4Jz3Clz3XdESr77backuL96RvXv4j5XCgAAvlXUWKVZN16CbSu6Qzno+DjioCzFbZwwHrVcg9pgooe6o7KU4LiGcl8cWQo6XoKlWQm2/Ruh7AYAAMAtdf/JcVmU3QAAAHd1o1+x2N29au5A2Q0AAHAzUXGqhXuVnju63Y1TdgMAANzVXqWni/jSx46aTf39ofUbAADANUS1rbYXL+h2P6Vy+1Rbxr9lAAAAgMNRdgMAAACHo+wGAAAADrdD2X3a792f/wv+558RAAC857S39hsnKlPeWGEXJ5zX6+9+rr0WLOvsteyMznl0+qWWtZGDnHYiO/+MAAAg07t4qWVt5CBvnOi0axs75zLiFEf8t5h7Xfw5mzDQOXn+z1fVdwv5ch082mknsvPPCAAAsvwuVt8t3KUg6U55Y52NTjhjPJF8ih3PuNdS3XX2WnzGazW/Luuz/1AAAABfjoLkakrNjS4+sAAAAHgf//6ZdOw+xWNw65pPmOT8dlaOdBNkMAQAAO7IL/el9/t8wrzBlG7c+RoqCWW0cLzNaSOZR9sEB5cSxtopOaJ+STCPLiWENqeN2FI8DPJzfymnO7RkOvF1cRH6dRn/X4LKZb2UUIZamu58B/XT03OaDjMPRStDAADgjvLLXYeDt78OBwllaMnSlOh3V8j5ZUrIozp0QukrwRRRc5opolEfqpP7Gh3LOXm6lAWjtSc1jy4liBOsjUheMK8W/XbxHFTfy+Zk9fOQ2tja+L/5HKsiM6e1U2YSspmTZmVxH+Z+sfGMAADgHBcvSAZToj+zQs4ZX2FeUB1HZq68zNUUr6C+fjpSlLOENjlH2tGs3Ox2g03oXkkOdhOCd0nazpJmq/4t1s0trK4YlFloooYmE2bOtZfzzwgAACbFazq3cNmC5I0pUi4mX0YxGLLVy1BC/HT7uPYa4vrf2EnTgltW2NfKHutu3cJFHkzLVyjXvEgAAPAGlyJ+3V+2INni/JsqGxsNx3nt2fphXPaDrs9rND43AAA81fULklflukWVDC5LD8vPSJ2ZyvPlp3rlcta3feWLBAAA2z3vXV8KGCrvK9OTimc0X3OH5zzSl24bAADggkrxfbRS3FPrT4qN0pN66Xkdsrs6fffJaWhLwkHOPyMAADjUlnpjNWHJG1NCydci7gyucMkbl/HqNcv4Ml7Sveb3rkre2IQZby/42rw4jc40ucX5sqLfzppPyJ08q2jzwyC/1a4QnZdWAAAAh/Kr+bIFSXh1yuRqIfqTNx48MXfyCjrU6PyyhabvxZf06rLOL3Nz3J2c8AatUNpYZzxP8yo5WJ5T2w+RozTFo5UHOZMgZdQTi6X86PvnUkf9pRWi4z4AADiHX9Duu0l5cbf94Je44tHKO30mQcqoJ7YGU0JERKMWo4qo5VmeWIaCIm0/OE3xdsG8Tij5bX9SO71E2o777SVFywm5H5SvYDRP10R1pE0IERGN5o76bSeaF2k5s6szGGuNm5V4tGIwJOOEMurOEicrLR/mJqtBHwIAgPP5jbzUrMSjFYMhGSeUUXcGnK/M0slN1GnjtjSU42pZibtjHs3xHFQbKwl5Yrd106wN5ohaVuLumEcVL53c2qDMBNXGhjU5AAAAsCYqzvEXvU8y/sJ7gLIbAAAAW31J5T24x9VynLIbAAAAO/ie77zb21ytuQNlNwAAAPbx3m9f3EjcoO4x6uzcZm6csnva78/tGwAAADZT8Z3bDMpuAAAAYM7P70pbRtkNAAAAHI6yGwAAADgcZTcAAABwuMWyW/9V5hXsfiXXuTUAAPBIDyg2LnULh17MaXfaOclp5151nSsBAACYQfWyryftZ+c+5v9nUI62y5W0j+o6N1jwpxQAgLv7VJmxexVxkXpp98v4YGVIoQcAAAAc7uFl942+P+arbgAA8B6qiEmf3aipk8cl5mYl0vZ9GNpIcMSjOlyylON4Hs0d90M5NMWXRrOS6Z+5WYn4UJH8Ux33RZE2HnKwzWkjAADckd9o3ffaYCg4XnJ8mIOSIyXBh4PI2Gp+NyEHu/F82HJaO1qGcoKDpojjZXRVnl7mOuJRHY7l5JJf4vmnOu6HcphpaJDwkqk1/Psu5Xdf1I+f+WrUd5oOFVEw+o6LR3NCofw2J8c1pGDwoYeU3FUWWUoLOTOaMzVRHfeD+vr56lwlOOj86JS+Z+lQkTILAIB7yW+0/KYz9fMrT819iU6erkPPUlA/1XHfOYrnKdJGBrygpugUWZsgOlTH/aD+0qgMTpqHouW4+7aUPEMLeq6D+umlSo7jLc3KyQq646FojjtT8aB1luR1dLjR7ALj8/mCcr+NZDnYjrYn6i7SGucsLaJtfU+eqP78U5k5qXPy4tHPcfXbCAAAT1Lebn4nSunEz0HEciQndJO3KMVGu/i4GtHQfI0hqyfNPBqdcWZYTRjIc/O52jUn73d8MYPRfPZi/Dje8+LT+7cjLmj3BVe1T3TwDKRMWU3OCfNzlRk/3QAAwB11X+KqATTUJsTouMAIMWu1kCjySXNHxmd8KXmjjYtvvNR262KF7ffbrLpMJ2uv47PKLpx2eXGi7rlmdmlpbpduMDcAAL5EefHNvz0HjljzHLrs3S/4pbLkpWTbfc9nFnzvUg91sct5l3Y2Wn4GBymP+aUnumUuAADfSW/MaOUtr0O/TNWZrASW1vwqL5UlLyV3aVa0vfZ8acHtl3qQ1y5Et6Grb2/yU3Q9cTGnXU85V3mcGlrapfFcAACQjd/yCkaO02aM17wy369+br/+sglaeclLycXuez5esMRfutTjXOMqNvCmn2/pSc+Yn1s+KBf53AAAcILVt3wk6JX66ot1MvlLzO9eeClZdt/zyQXfuNRDvVzE6er1KT/C+X8YfEdZOczKUPdSl3ZpZu7A4KoAAPg2N3otdosN0VA3YZAfQ6tVxOpJy9B4wZeSt9Pp3jvL9kvt7k85fMPmBfaw/Ta8Ql7q1c2KBLex1YSBmbnK8adEl1SCAAB8Cb863Qk52LZVzsnJMxNbeanVFcrp2te6FlF7TzsxR6KfT/rSWZaSIz6zjnNy8lJ/xmDBmaUmc9y266yRl+6eZukj4v5Mx/0QCyoSLfpeP6d1O9FKcj70Uh5SR3Lfs8QTl3gptW7y0gpLc9XpBs2HSnN/puM+AAB3UV58+TD65S2ZKT9aPpTBmv651FFfU3QYzStEJ5rTQu5rNCgYzROlPSwRa+OKtMt6kcFJPeRR9SX3u8nmtJYzy8SySF4/+hrSobifV4iWD9WPnxoqCeo4qI7kfvAUicMSeUNnh7RuboUuNMvJHhpHHJRxMA+1waVDyYfuu1k32KWE1fx2l4IinlgSxsEcz0HHxxEHAQC4kfIiy31xJLdu3EowH+Ymq0EfiuNu2VJcxqO2VGMsTfRQGdVhO5ojagqWISuHXZ6lzNzP2rgjbm08H6qfIzq0HHTfLVuKv61TdgMAAFxft/rER/AsZrxcdse2YhW7BADAoQav2meXgBesMZ694TuafXSxoWqBnV3CLgEAcCa9c7OIPPIVfOUag5pn0mzZbXvtrD86pf8MfP4AADhUvGr1tlUV4fb4V/DDblBPre0/0uzN6cO945P2gm4P8KR7AQDg+vzmdXuqp96g78vtwR79b4qun9/vbQAAAJBSJk22Db6v7AYAAABOR9kNAAAAHI6yGwAAADjcC2V3+c9LP/Vfm37qvAAAAGNUKZ918f2furSL3MPFtxIAAABYMlXGdv/3XM7/H3k5/4wAAADz7lirPOk7zYvvP98eAwAAAIej7AYAAPhS/PrumVY2W79O3X0kbdzJipfRUBIyB7sJ3aB5tE1wcCkBAABcnF/i7as8R7oJwfHV0SIH25w2EtpIcGZ3dFWetbSI43moDZZIiVtOKEPBwRIPDjpBh1keGo8WOTiTY07ujp5pdPK4Mv2KTLR8ld2LzsklX3KCDpXjjvoazRRUc6YpolEfqpP7GgUAADeit7ne8n6V6/2uIclpOpQcL9NF/aWJuZ+nO5JnKVjkzLzCpLxmXkqHpn475IiViPuO6ywSnZwsCrb57qhfckQ5eUhBU39pYu6PcywnK1/BT1k8c7kmX2vIl76kJOiebWk1dXJkcBlWpmtKXkSdHAEAALeT3+P5tT75iu/m5EVCt4pQv41k3WCxmlDkNcfr57RQyqd5+Szq5MhL5VzWvZ42LZRFBo+jWIpnqwlH6z8W3+RLyp56+mCvu0O2ehlKiJ9uAAAAM55RRZx2F92VV8u5+WJSi+gW1J5n53v6yDbFEy0NAAA8QHmtv1pjzExXTm47KgseVyP54t0uqFzYCY+jrHB+jVrsdv5yVx+/MQAA8AyqK6K9V4RtnL7dxy/gUs7fjfPPuGTP6jhuJt9P3B4AAMAWKidKjTFv4/TtPn4Bl3L+blxq//++ll2df2PaUCuHAADgplwzvWdm+qFVxMbrn3foXexlZjf2vZGZM56pfze6vpdutSTnOxysNt6I7ZcBAAAw6RlVxEF38V45p/xxvbfkeUXdyg35hnNnaRdWdycnRH/+GXhi7uQVdKjR9x4tAAC4Jr3fcyfk/tjS9NOqCJ/XnZBPusWrd+EzOtnK4ZKcFv32XON1PLq0TvTVwi6PwydyJ+T+aRbPWW7eh+rkG3A/hnSolncq+p5YRnXY9qWk+dALOiIlv+0DAIC7KK/1fOifS51og+nqOyIl3/2Zjlo+DKsXoP4SzXK/7ai/dBeiQyVH82h01IKH1JHcl5IfTYeF11GCc9wpc913REq++23HLUfC6hlP9v8X2BMX5ObDEldTsAy1uqM5qFaUIXfMozmeg2oAAOB2yqs8H+YmbXDp0BxZCjo+jrStzcmH7g84OWeuBltl1B1ph3JrjUdlKcFxDeW+OLIUdLwE29am5cOPGJXdAAAAOM6nvnbFR1B2AwAAfAA197eh7AYAAPgAau5vQ9kNAACATfTfLLZ9ZOwKAAAANtF/p5gbWk3Z/fP78AYAAIC7KwXeG+10fNsNAAAAHI6yGwAAADgcZTcAAPgi/Ad/59u45495XnzuAADAV6Dgvqnfv/9/m38APn0AAOArPON/YeOOBej2nX9G5U3ZDQAAgKt7QOVN2Q0AAHAP/JLMrXeAshsAAFxaVFq5ZTnSTZDBUMuZnqXDLA+V0RzpJoiHPJojDoY2mPvmnHYoOO4cHWZ5aDxa5GA3p42Ik5cSHuYLbhEAANyTqjH9ZrB/OVj1WS7UcpoOMw9FK0OF1nHfs3QoyslDCupnN02HmYfyqPrquB/Uz8GSENoFfcbSL2minDykoKm/NDH3S05OyHKy8hUcc+ZNrd0fAADANeSqK5druV+USm4pTcqaRbcozGlleruCqNzsUny1+izKgmXxOHSkDIXVm7KyiCZGP8fdt26wNZNjr+7Pddz2wgEAAIZcGm60fQVrS8bVwjSmDBK6Najyx+Xp/E1pnfjphvewcwAA4KJKSXqFgu/oS9LiJ9/pzE0pJ7ctygpfUsp/x10CAIDbippMbWOpt6MLXtJ259/U+Wf8LMpuAABwXVGThSjLLlVzh+MuScvqLKeVpOfv8wWf7NH+vmMAAIDrcWV2HRe8pO1mbko5Vg5f9chtXLVtzwAAAK5KVd3GAjHsWCN2L6m9QqetnnRwj+O5W26qe7rTvHfNV/DRbQMAAFjjIi9Xey9Vfu0K0RmvMDma08ZTikh2e0+ZmA+j361Nx+fy6NJS0VcLu9S+PpE7IfeLwdAt3PzyAQDAc5WCLx/651JH/aUVouN+V4xqimbliVIWjL5/LnXU9xTJi2eDoJZygldQPA8VEc85TnOnTHffESn57redkuD+6hkf6f/vHgAA4HqiCHMrh7nJatCHM/KszHEN5cPcZDW4ZKkAXZroeDuULeU4rqHcF0eWgo6XYGlWgrk/sJpwZZTdAAAAuLoHfBFO2Q0AAHAtUWIie8Yvn/BUAQAALiGKS7XwgCpzL8+ouQNlNwAAwF9c8pb++XasMq9zU297zL9AKLsBAAD+EuVdaSc74rxe0w2fQtkNAACu5+eXRhu1G6LsBgAAAA738/v71z8X/vjjDx0DAAAA2B3fdgMAAACH+9e33X/++effQaDiE/Ip/r9Esfm3wJ+UZ+A5fhCbj6eKzzbfdgMAAACHa8ru3x/anRoAAADugG+7AQAAgMNRdgMAAACHo+wGAAAADkfZDQAAAByOshsAAAA4XL/s/vlvbQAAAADe1i+of//3V2v7eBX/YgEAAECgKgQAAAAOR9l9IL7qBgAAgLxWGObf81Y/V5ZtJORImzCIONhGQj5sR8XxdqhVkv0zNysRHyqSf6rjvijSxkMOtjltBAAAALcwW8Hlak99/8K3DhVRMPqOixPyoSJ5SnDESkQTc98Jjgf1u0MtL6LmZM1Vx/2gvn6+OlcJDjo/OqXvWTpUpMwCAADALcyWby74cr+NZDnofht5VZ44XiSnhflSNa+5Ze6S7oVFP8fVbyMAAAC4o2d+a6pCNn66rSo54xo3knPC/Fxlxk83AADQ8ftDo+3cPu3JdZ++Ic5tbKkO1sRxifxSDZ0vSQ0AAADPxtetf8mF70sFdNgyFwAAAF+CIvEf5VvnUj1rSMH4mTPDeC4AAADw5AqxlL8z1XApoF8yP/eNCwMAAMCtfUvFNy5ty2i3elYwMsvozNwBam4AAG4kXtzb3927LDJw9PrneMZdZPe4G2/65ANw7at8TRkXxDPLLpmZW65BV1WCAABg1cxr9wh+cW+xyyK4qf6Tz58J9UtkpqPmw5mO+6pEFYnmwtRx6XbUL7XsamkbCZqr1s1fWmRprjrdoPlQae7PdNwHAOBLfPDdF6/s8hJ/wy6LFO2eHHGWQ3Uf6+3uYlX/w6v7HLQ2rY2U1ia0EQdDCZaOm6wGx5Swmh+fiXZIEU8sCeNgjueg4+OIgwAAfBW+eMId8bEFAAD30P3+68s94F8g3/OPKMruWfzDGgCAKxhX3vG+9itb/fYN7ng76ohHddjVJjiyFB9wzlJmO5o77odyaIovjWbOafMdyUHJQ+2olASnOWJtRBTvjubgUs4HXelaLik/M/6FDQDAp8S7OL+I23LK72v3I19TunGvplENSclx3JTcJuhQHfeD+jmS5dWc4zWlJGjUyTleJlp3hVZeQVMyDbWLaJbinuJRKzk6FAeDVutqV1BmnqJ+zrmIy1zI5enJAQCAa3KZVfoDOadML0rplpMLxbeUet2zL52uWLqw91ZQJ0dCGe3eac633e+i9H2Y+5dC2b1CT+6aDw8AgO+k93K34NvdLjXAfMXZam/z1cpk+wqideKn27w2eftdBK3w0pV80E0u8xw/v/drAAB8gair3igTW6XUO6hce7UWPOeq9qKrzc1Bu0sdfDJ2BQAA3EBUcrk5+AYvkivFj7vmVb3kAbdwKMpuAABwA/o+Nbf3RFEYtqwwQ4vrXDNl6DlXdagH3MLRKLsBAMClLZWtCqram+TS8FKueVVLyobr8F638Cn/3rmh2NC80eXwNJ86LwAA+EKqOt4oKP2vgo3FqNfJXqqFtq+wZH6Rg+5CNu7waaZuN+7wpX05yEUuAwAAnGbm1f9qeeD8PHGpf5qZq3LrWorb6gpjrm7zIrnk9bJ5/dwPmqjW6gaLnBP9u9TcYeLm/t7Q9pa6wUOdf0YAAPBBLrBWS7Toq/mw7URzIdEe5hoj+kpQXEM6lG7HfctrSk5z32mK5EP1yzpx6Ig6nqiO5P5ghWJpBWnXKR1NyYdtjsShIvqZJ6ovue8pCkbToSPutx33P+gClwAAANCjMsvFVpFH29bNKZF8WLRxR3K8G7Qo9UowJ6u18XxojuSg5Lj7btYNtnKaWrE0VOK5bw4uxcuhW9aN56Dj3eAHUXYDAAAAh1spu/WdfPdr+TbuZMXLaCgJmYPdhG7QPNomOJgT3PchAADAvigwUIw+EfFx8dfy+aMT/faTlJNLvuQEHSrHHfU1mimo5kxTRKM+VCf3Neq+m3MAAAC2UwWiAsPlBxAWq85Sj+bPjQrWsZIQq5UVLK+mTo4MLsPKdH/QSzxHrI0AAIAvFPWDq47cfxs1Bor+Z8qV60vKB9TTux9cjY4/06uXoYT46TajpPGnAgAARD1Q2ns2TseDzRWq0+Zr3x358+226iPXCQAAZv380mg7t0/brfbMxe6Vi9q7XCcAAACeZM+qs3zTfOXK+xbXCQAAgMfYv+QsRe0JSt08WUaff50AAAD4Wv0SVfXoS18Dl+Rc0Q5WGxe+2y+jNbhOAAAA4CArVaqL1NxZKm2X4pYToj9f8npi7uQVdKjR1WWVBgAAAJxmsQItFa0P1XHlqlGJIR2q5fI3+p5YRnXY9qWk+dALOiIlv+2HyFFErawAAAAA7O7fRe6/RT3q5sMSV1OwDLW6ozmoVpQhd8yjOZ6Dao7rZ4kDAAAAxxmV3QAAAAB2QdkNAAAAHI6yGwAAADgcZTcAAABwOMpuAAAA4HBN2f3z+70NAAAAOAbfdgMAAACH+/n9/etb3j/++EPHAAAAAHbHt90AAADA4f75thsAAADAcfi2GwAAADgcZTcAAABwOMpuAAAA4HCU3QAAAMDB/vOf/wPYSZ1ujVKJJAAAAABJRU5ErkJggg==" /><img alt="" width="991" height="1089" src="data:image/png;base64,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" /><img alt="" width="1001" height="1046" src="data:image/png;base64,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" /></p><p><img alt="" width="1146" height="224" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>* Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy<br />or early after treatment discontinuation (see section 4.4).<br />**See section 4.4<br />***In pooled clinical trials, the incidence of headache with venlafaxine and placebo were similar.<br />Discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms.<br />Dizziness, sensory disturbances (including paraethesia), sleep disturbances (including insomnia and<br />intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, vertigo, headache and flu<br />syndrome are the most commonly reported reactions. Generally, these events are mild to moderate<br />and are self-limiting; however, in some patients, they may be severe and/or prolonged. It is therefore<br />advised that when venlafaxine treatment is no longer required, gradual discontinuation by dose<br />tapering should be carried out (see sections 4.2 and 4.4).<br />Paediatric population<br />In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in<br />children and adolescents (ages 6 to 17) was similar to that seen for adults. As with adults, decreased<br />appetite, weight loss, increased blood pressure, and increased serum cholesterol were observed (see<br />section 4.4).<br />In paediatric clinical trials the adverse reaction suicidal ideation was observed. There were also<br />increased reports of hostility and, especially in major depressive disorder, self-harm.<br />Particularly, the following adverse reactions were observed in paediatric patients: abdominal pain,<br />agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In postmarketing experience, overdose with venlafaxine was reported predominantly in combination<br />with alcohol and/or other medicinal products. The most commonly reported events in overdose<br />include tachycardia, changes in level of consciousness (ranging from somnolence to coma),<br />mydriasis, convulsion, and vomiting. Other reported events include electrocardiographic changes<br />(e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia,<br />bradycardia, hypotension, vertigo, and death.<br />Published retrospective studies report that venlafaxine overdosage may be associated with an<br />increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but<br />lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine<br />treated patients have a higher burden of suicide risk factors than SSRI patients. The extent to which<br />the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in<br />overdosage, as opposed to some characteristics of venlafaxine-treated patients, is not clear.<br />Prescriptions for venlafaxine should be written for the smallest quantity of the medicinal product<br />consistent with good patient management in order to reduce the risk of overdose.<br />Recommended treatment<br />General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs<br />must be monitored. When there is a risk of aspiration, induction of emesis is not recommended.<br />Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients.<br />Administration of activated charcoal may also limit absorption of the active substance. Forced<br />diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific<br />antidotes for venlafaxine are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antidepressants - ATC code: NO6A X16.<br />The mechanism of venlafaxine&#39;s antidepressant action in humans is believed to be associated with its<br />potentiation of neurotransmitter activity in the central nervous system. Preclinical studies have shown<br />that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin<br />and noradrenaline reuptake. Venlafaxine also weakly inhibits dopamine uptake. Venlafaxine and its<br />active metabolite reduce &beta;-adrenergic responsiveness after both acute (single dose) and chronic<br />administration. Venlafaxine and ODV are very similar with respect to their overall action on<br />neurotransmitter reuptake and receptor binding.<br />Venlafaxine has virtually no affinity for rat brain muscarinic, cholinergic, H1-histaminergic or &alpha;1-<br />adrenergic receptors in vitro. Pharmacological activity at these receptors may be related to various<br />side effects seen with other antidepressant medicinal products, such as anticholinergic, sedative and<br />cardiovascular side effects.<br />Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.<br />In vitro studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine<br />sensitive receptors.<br />Major depressive episodes<br />The efficacy of venlafaxine immediate-release as a treatment for major depressive episodes was<br />demonstrated in five randomised, double-blind, placebo-controlled, short-term trials ranging from 4<br />to 6 weeks duration, for doses up to 375mg/day. The efficacy of venlafaxine prolonged-release as a<br />treatment for major depressive episodes was established in two placebo-controlled, short-term studies<br />for 8 and 12 weeks duration, which included a dose range of 75 to 225mg/day.<br />In one longer-term study, adult outpatients who had responded during an 8-week open trial on<br />venlafaxine prolonged-release (75, 150, or 225mg) were randomised to continuation of their same<br />venlafaxine prolonged-release dose or to placebo, for up to 26 weeks of observation for relapse.<br />In a second longer-term study, the efficacy of venlafaxine in prevention of recurrent depressive<br />episodes for a 12-month period was established in a placebo-controlled double-blind clinical trial in</p><p>adult outpatients with recurrent major depressive episodes who had responded to venlafaxine<br />treatment (100 to 200mg/day, on a b.i.d. schedule) on the last episode of depression.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine<br />(ODV). Mean &plusmn; SD plasma half-lives of venlafaxine and ODV are 5&plusmn;2 hours and 11&plusmn;2 hours,<br />respectively. Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral<br />multiple-dose therapy. Venlafaxine and ODV exhibit linear kinetics over the dose range of 75mg to<br />450mg/day.</p><p>Absorption<br />At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine.<br />Absolute bioavailability is 40% to 45% due to presystemic metabolism. After immediate-release<br />venlafaxine administration, the peak plasma concentrations of venlafaxine and ODV occur in 2 and<br />3 hours, respectively. Following the administration of venlafaxine prolonged-release capsules, peak<br />plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours,<br />respectively. When equal daily doses of venlafaxine are administered as either an immediate-release<br />tablet or prolonged-release capsule, the prolonged-release capsule provides a slower rate of<br />absorption, but the same extent of absorption compared with the immediate-release tablet. Food does<br />not affect the bioavailability of venlafaxine and ODV.<br />Distribution<br />Venlafaxine and ODV are minimally bound at therapeutic concentrations to human plasma proteins<br />(27% and 30%, respectively). The volume of distribution for venlafaxine at steady-state is 4.4&plusmn;1.6<br />L/kg following intravenous administration.</p><p>Metabolism<br />Venlafaxine undergoes extensive hepatic metabolism. In vitro and in vivo studies indicate that<br />venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6. In vitro and in<br />vivo studies indicate that venlafaxine is metabolised to a minor, less active metabolite, Ndesmethylvenlafaxine,<br />by CYP3A4. In vitro and in vivo studies indicate that venlafaxine is a weak<br />inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2, CYP2C9, or CYP3A4.<br />Elimination<br />Venlafaxine and its metabolites are excreted primarily through the kidneys. Approximately 87% of a<br />venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%),<br />unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).<br />Mean &plusmn; SD plasma steady-state clearances of venlafaxine and ODV are 1.3&plusmn;0.6L/h/kg and<br />0.4&plusmn;0.2L/h/kg, respectively.<br />Special populations<br />Age and gender<br />Subject age and gender do not significantly affect the pharmacokinetics of venlafaxine and ODV.<br />CYP2D6 extensive/poor metabolisers<br />Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive<br />metabolisers. Because the total exposure (AUC) of venlafaxine and ODV is similar in poor and<br />extensive metabolisers, there is no need for different venlafaxine dosing regimens for these two<br />groups.<br />Patients with hepatic impairment<br />In Child-Pugh A (mildly hepatically impaired) and Child-Pugh B (moderately hepatically impaired)<br />subjects, venlafaxine and ODV half-lives were prolonged compared to normal subjects. The oral<br />clearance of both venlafaxine and ODV was reduced. A large degree of intersubject variability was<br />noted. There are limited data in patients with severe hepatic impairment (see section 4.2).<br />Patients with renal impairment</p><p>In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance<br />reduced by about 57% compared to normal subjects, while ODV elimination half-life was prolonged<br />by about 142% and clearance reduced by about 56%. Dosage adjustment is necessary in patients with<br />severe renal impairment and in patients that require haemodialysis (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies with venlafaxine in rats and mice revealed no evidence of carcinogenesis. Venlafaxine was<br />not mutagenic in a wide range of in vitro and in vivo tests.<br />Animal studies regarding reproductive toxicity have found in rats a decrease in pup weight, an<br />increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation. The cause<br />of these deaths is unknown. These effects occurred at 30mg/kg/day, 4 times the human daily dose of<br />375mg of venlafaxine (on an mg/kg basis). The no-effect dose for these findings was 1.3 times the<br />human dose. The potential risk for humans is unknown.<br />Reduced fertility was observed in a study in which both male and female rats were exposed to ODV.<br />This exposure was approximately 1 to 2 times that of a human venlafaxine dose of 375mg/day. The<br />human relevance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose PH 101<br />Lactose Monohydrate<br />Sodium Starch Glycolate<br />Yellow Iron Oxide<br />Colloidal Silicon Dioxide Aerosil 200<br />Magnesium Stearate<br />Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-PVC/PVDC Blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October-2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>